Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug-drug interactions are typical indications for TDM. However, the potential benefits of TDM to optimize pharmacotherapy can only be obtained if the method is adequately integrated in the clinical treatment process. To supply treating physicians and laboratories with valid information on TDM, the TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued their first guidelines for TDM in psychiatry in 2004. After an update in 2011, it was time for the next update. Following the new guidelines holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs.

[1]  K. Sangkuhl,et al.  Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update , 2017, Clinical pharmacology and therapeutics.

[2]  G. Gründer,et al.  Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism , 2017, Schizophrenia Research.

[3]  H. Möller,et al.  A proposal for a psychopharmacology–pharmacotherapy catalogue of learning objectives and a curriculum in Europe , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[4]  J. Turgeon,et al.  Highly sensitive LC-MS/MS methods for the determination of seven human CYP450 activities using small oral doses of probe-drugs in human. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  G. Gründer,et al.  Clinical response in a risperidone-medicated naturalistic sample: patients’ characteristics and dose-dependent pharmacokinetic patterns , 2017, European Archives of Psychiatry and Clinical Neuroscience.

[6]  Manfred Uhr,et al.  ABCB1 genotyping in the treatment of depression. , 2016, Pharmacogenomics.

[7]  T. Tomson,et al.  Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring. , 2016, Epileptic disorders : international epilepsy journal with videotape.

[8]  G. Gründer,et al.  Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment , 2016, Journal of clinical psychopharmacology.

[9]  J. Wade,et al.  Brivaracetam Population Pharmacokinetics and Exposure‐Response Modeling in Adult Subjects With Partial‐Onset Seizures , 2016, Journal of clinical pharmacology.

[10]  K. Lasseter,et al.  Relative Bioavailabilities of Lisdexamfetamine Dimesylate and d-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink , 2016, Therapeutic drug monitoring.

[11]  Meenakshi Singh,et al.  Concentration of antiepileptic drugs in persons with epilepsy: a comparative study in serum and saliva , 2016, The International journal of neuroscience.

[12]  S. Jacob,et al.  An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs , 2016, Drugs in R&D.

[13]  M. Gerlach,et al.  Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry , 2016, Expert opinion on drug safety.

[14]  C. Johannessen Landmark,et al.  The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice , 2016, Therapeutic drug monitoring.

[15]  R. Grohmann,et al.  Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012. , 2016, Journal of affective disorders.

[16]  L. Friedhoff,et al.  Switching Opioid‐Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics , 2016, Journal of clinical pharmacology.

[17]  G. Gründer,et al.  Pharmacokinetic patterns of risperidone-associated adverse drug reactions , 2016, European Journal of Clinical Pharmacology.

[18]  C. Eap,et al.  Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients , 2016, Clinical Pharmacokinetics.

[19]  G. Sivaramakrishnan,et al.  Interaction of Citrus Juices with Cyclosporine: Systematic Review and Meta-Analysis , 2016, European Journal of Drug Metabolism and Pharmacokinetics.

[20]  Jin Wang,et al.  Characterizing novel metabolic pathways of melatonin receptor agonist agomelatine using metabolomic approaches. , 2016, Biochemical pharmacology.

[21]  Yingjie Guo,et al.  Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine , 2016, Therapeutic drug monitoring.

[22]  Juming Yu,et al.  Identification of the Human SULT Enzymes Involved in the Metabolism of Rotigotine , 2016, Journal of clinical pharmacology.

[23]  K. Nemoto,et al.  Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2 , 2016, Therapeutic drug monitoring.

[24]  S. Johannessen,et al.  Therapeutic Drug Monitoring of Clobazam and Its Metabolite—Impact of Age and Comedication on Pharmacokinetic Variability , 2016, Therapeutic drug monitoring.

[25]  Ling-yue Ma,et al.  Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy , 2016, Therapeutic drug monitoring.

[26]  Barbara Błońska-Fajfrowska,et al.  Directional reflectance analysis for identifying counterfeit drugs: Preliminary study. , 2016, Journal of pharmaceutical and biomedical analysis.

[27]  M. Gerlach,et al.  Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice , 2016, Journal of Neural Transmission.

[28]  A. Patkar,et al.  Precision medicine for psychopharmacology: a general introduction , 2016, Expert review of neurotherapeutics.

[29]  E. Seifritz,et al.  Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects. , 2016, British journal of clinical pharmacology.

[30]  H. Naik,et al.  A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder , 2016, Basic & Clinical Pharmacology & Toxicology.

[31]  C. Hiemke Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology. , 2016, Current drug delivery.

[32]  Kaarlo Simojoki,et al.  Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients. , 2016, Drug and alcohol dependence.

[33]  C. Hiemke,et al.  Consensus guideline for therapeutic drug monitoring in psychiatry (2004): Bibliometric analysis of citations for the period 2004–2011 , 2016, Nordic journal of psychiatry.

[34]  C. Bundgaard,et al.  P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood–brain barrier in vivo , 2016, Neuropharmacology.

[35]  P. Heutink,et al.  A common polymorphism in the ABCB1 gene is associated with side effects of PGP-dependent antidepressants in a large naturalistic Dutch cohort , 2015, The Pharmacogenomics Journal.

[36]  S. Gopal,et al.  Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: A phase‐1, single‐dose, randomized, open‐label study , 2016, Journal of clinical pharmacology.

[37]  Jianping Cai,et al.  Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine , 2016, Drug design, development and therapy.

[38]  E. Molden,et al.  Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype , 2016, Therapeutic drug monitoring.

[39]  H. Neels,et al.  Determination of Common Antipsychotics in Quantisal-Collected Oral Fluid by UHPLC-MS/MS: Method Validation and Applicability for Therapeutic Drug Monitoring , 2016, Therapeutic drug monitoring.

[40]  A. Serretti,et al.  Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis , 2016, European Neuropsychopharmacology.

[41]  F. Holsboer,et al.  Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. , 2016, Journal of psychiatric research.

[42]  C. Eap,et al.  Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone. , 2016, Journal of clinical psychopharmacology.

[43]  B. Stegmann,et al.  Quantification of Methylphenidate, Dexamphetamine, and Atomoxetine in Human Serum and Oral Fluid by HPLC With Fluorescence Detection , 2016, Therapeutic drug monitoring.

[44]  H. Frieling,et al.  Psychopharmacological treatment of 1650 in-patients with acute mania-data from the AMSP study. , 2016, Journal of affective disorders.

[45]  H. Chu,et al.  An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics , 2016, Journal of clinical pharmacology.

[46]  SH Jang,et al.  Therapeutic drug monitoring: A patient management tool for precision medicine , 2016, Clinical pharmacology and therapeutics.

[47]  F. Larsen,et al.  Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. , 2016, British journal of clinical pharmacology.

[48]  Janice M. Fullerton,et al.  Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study , 2016, The Lancet.

[49]  Tadakatsu Nakamura,et al.  Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment) , 2016, Drug design, development and therapy.

[50]  P. Neuvonen,et al.  Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions , 2016, Pharmacological Reviews.

[51]  J. Aronson,et al.  The law of mass action and the pharmacological concentration–effect curve: resolving the paradox of apparently non‐dose‐related adverse drug reactions , 2016, British journal of clinical pharmacology.

[52]  S. Kasper,et al.  Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program , 2015, The international journal of neuropsychopharmacology.

[53]  A. Serretti,et al.  HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis , 2015, The international journal of neuropsychopharmacology.

[54]  N. Freemantle,et al.  Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. , 2015, The American journal of psychiatry.

[55]  B. Pollock,et al.  Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. , 2015, Schizophrenia bulletin.

[56]  M. Krasowski,et al.  Therapeutic Drug Monitoring of Newer Antiepileptic Drugs , 2016 .

[57]  Yunli Yu,et al.  Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy , 2016, European Journal of Drug Metabolism and Pharmacokinetics.

[58]  Chuan-Yue Wang,et al.  Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese Volunteers , 2016, Clinical Pharmacokinetics.

[59]  C. Hiemke,et al.  Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels , 2016, Psychopharmacology.

[60]  E. Clementi,et al.  Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings , 2016, European Journal of Clinical Pharmacology.

[61]  R. Findling,et al.  Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders. , 2015, Clinical therapeutics.

[62]  U. Hofmann,et al.  Heritability of metoprolol and torsemide pharmacokinetics , 2015, Clinical pharmacology and therapeutics.

[63]  W. Rascher,et al.  The Safety of Drug Therapy in Children. , 2015, Deutsches Ärzteblatt International.

[64]  A. Rettie,et al.  P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms , 2015, Drug Metabolism and Disposition.

[65]  Diansong Zhou,et al.  Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder , 2015, Journal of clinical pharmacology.

[66]  Xiaomeng He,et al.  Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular, and Intravenous Administration of Levosulpiride After Single and Multiple Dosing in Healthy Chinese Volunteers. , 2015, Clinical therapeutics.

[67]  Dan-Qi Liu,et al.  Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy , 2015, Epilepsy Research.

[68]  E. Molden,et al.  Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data , 2015, Therapeutic drug monitoring.

[69]  D. Rollins,et al.  A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults , 2015, Clinical Drug Investigation.

[70]  Laishun Chen,et al.  Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. , 2015, Clinical therapeutics.

[71]  Sarah L. Greig,et al.  Brexpiprazole: First Global Approval , 2015, Drugs.

[72]  E. Haen,et al.  Retrospective Analysis of Therapeutic Drug Monitoring Data for Treatment of Bipolar Disorder with Lamotrigine , 2015, Pharmacopsychiatry.

[73]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors , 2015, Clinical pharmacology and therapeutics.

[74]  M. Miura,et al.  Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine , 2015, Journal of clinical pharmacy and therapeutics.

[75]  S. Kasper,et al.  The serotonin transporter in psychiatric disorders: insights from PET imaging. , 2015, The lancet. Psychiatry.

[76]  Dan-Qi Liu,et al.  First Analysis of the Association Between CYP3A4/5, ABCB1 Genetic Polymorphisms and Oxcarbazepine Metabolism and Transport in Chinese Epileptic Patients with Oxcarbazepine Monotherapy and Bitherapy. , 2015, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[77]  I. Grabnar,et al.  Dried blood spots for monitoring and individualization of antiepileptic drug treatment. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[78]  J. den Hartigh,et al.  Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers , 2015, CPT: Pharmacometrics & Systems Pharmacology.

[79]  Christina N. Lessov-Schlaggar,et al.  Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption , 2015, PloS one.

[80]  C. Eap,et al.  Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort , 2015, Clinical Pharmacokinetics.

[81]  L. Citrome Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder. , 2015, Drugs of today.

[82]  A. Babiskin,et al.  Metabolism of Bupropion by Carbonyl Reductases in Liver and Intestine , 2015, Drug Metabolism and Disposition.

[83]  S. Krähenbühl,et al.  Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study , 2015, Clinical Pharmacokinetics.

[84]  Laishun Chen,et al.  Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans , 2015, Drug design, development and therapy.

[85]  D. Shang,et al.  The Elimination Rate after Clozapine Overdose in Chinese Schizophrenia Patients: A Population Pharmacokinetics Model Study , 2015, Pharmacopsychiatry.

[86]  F. Holsboer,et al.  ABCB1 gene variants and antidepressant treatment outcome: A meta‐analysis , 2015, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.

[87]  A. Fellgiebel,et al.  Therapeutic Drug Monitoring for Patients With Alzheimer Dementia to Improve Treatment With Donepezil , 2015, Therapeutic drug monitoring.

[88]  H. Neels,et al.  The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography - tandem mass spectrometry. , 2015, Drug testing and analysis.

[89]  Iain M McIntyre,et al.  Postmortem distribution of trazodone concentrations. , 2015, Forensic science international.

[90]  W. Cawello Clinical Pharmacokinetic and Pharmacodynamic Profile of Lacosamide , 2015, Clinical Pharmacokinetics.

[91]  D. Spyker,et al.  Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens , 2015, Journal of clinical pharmacology.

[92]  C. Hiemke,et al.  Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey , 2015, Journal of Neural Transmission.

[93]  Alan A. Wilson,et al.  Dopamine D2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophrenia—A [11C]-raclopride PET study , 2015, Schizophrenia Research.

[94]  S. Kittel-Schneider,et al.  Increase of Heart Rate and QTc by Amitriptyline, But Not by Venlafaxine, Is Correlated to Serum Concentration , 2015, Journal of clinical psychopharmacology.

[95]  E. Rozet,et al.  Estimation of the Time Interval between the Administration of Heroin and the Sampling of Blood in Chronic Inhalers. , 2015, Journal of analytical toxicology.

[96]  W. Haefeli,et al.  Use of Microdose Phenotyping to Individualise Dosing of Patients , 2015, Clinical Pharmacokinetics.

[97]  H. Boyda,et al.  Therapeutic drug levels of second generation antipsychotics in youth: a systematic review. , 2015, Journal of child and adolescent psychopharmacology.

[98]  H. Lerche,et al.  Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature , 2015, Clinical Pharmacokinetics.

[99]  Jean Petermans,et al.  Burden of frailty in the elderly population: perspectives for a public health challenge , 2015, Archives of Public Health.

[100]  Weilun Chung,et al.  The severe complication of Stevens–Johnson syndrome induced by long-term clozapine treatment in a male schizophrenia patient: a case report , 2015, Neuropsychiatric disease and treatment.

[101]  M. Mauri,et al.  “Long-acting” olanzapine in maintenance therapy of schizophrenia: A study with plasma levels , 2015, International journal of psychiatry in clinical practice.

[102]  J. Leon The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians , 2015 .

[103]  L. Fiellin,et al.  The impact of recent cocaine use on plasma levels of methadone and buprenorphine in patients with and without HIV-infection. , 2015, Journal of substance abuse treatment.

[104]  R. Altman,et al.  The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response , 2015, Translational Psychiatry.

[105]  L. Lazzeroni,et al.  ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial. , 2015, The American journal of psychiatry.

[106]  W. Cawello,et al.  An Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome , 2015, Drugs.

[107]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[108]  M. Ingelman-Sundberg,et al.  Pharmacogenomic information in drug labels: European Medicines Agency perspective , 2015, The Pharmacogenomics Journal.

[109]  H. Neels,et al.  Advances in detection of antipsychotics in biological matrices. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[110]  T. Fukami,et al.  A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. , 2015, Drug metabolism and pharmacokinetics.

[111]  J. Stingl,et al.  Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed‐function oxidase system, in the metabolism of psychotropic drugs , 2015, Journal of internal medicine.

[112]  A. Serretti,et al.  Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs , 2015, Translational Psychiatry.

[113]  Meenakshi Singh,et al.  Correlation of saliva and serum free valproic acid concentrations in persons with epilepsy , 2015, Seizure.

[114]  Roy G. Beran,et al.  The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy , 2015, Epilepsy & Behavior.

[115]  M. Bernardo,et al.  Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: Multilocus interaction in the mTOR pathway , 2015, European Neuropsychopharmacology.

[116]  G. Gründer,et al.  Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid. , 2015, The Journal of clinical psychiatry.

[117]  O. Spigset,et al.  Effect of Proton Pump Inhibitors on the Serum Concentrations of the Selective Serotonin Reuptake Inhibitors Citalopram, Escitalopram, and Sertraline , 2015, Therapeutic drug monitoring.

[118]  M. Meyer,et al.  Contribution of human esterases to the metabolism of selected drugs of abuse. , 2015, Toxicology letters.

[119]  P. Patsalos The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist , 2015, Epilepsia.

[120]  A. Jones,et al.  GHB Pharmacology and Toxicology: Acute Intoxication, Concentrations in Blood and Urine in Forensic Cases and Treatment of the Withdrawal Syndrome , 2015, Current neuropharmacology.

[121]  Paul Gallagher,et al.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 , 2014, Age and ageing.

[122]  A. Pruvost,et al.  A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail , 2015, European Journal of Clinical Pharmacology.

[123]  M. Kölch,et al.  Pharmakovigilanz in der Kinder- und Jugendpsychiatrie , 2015 .

[124]  David S. Miller Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly. , 2015, Advances in cancer research.

[125]  M. Gerlach,et al.  [Pharmacovigilance in child and adolescent psychiatry]. , 2015, Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie.

[126]  Seok-Yong Lee,et al.  The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes , 2015, Psychopharmacology.

[127]  Hilmar P. Sigurdsson,et al.  Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI , 2015, Journal of Neural Transmission.

[128]  H. Yamazaki,et al.  Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. , 2015, Current drug metabolism.

[129]  L. Greenhill,et al.  Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers. , 2014, Journal of child and adolescent psychopharmacology.

[130]  M. Trivedi,et al.  ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression , 2014, The Pharmacogenomics Journal.

[131]  J. Leon Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry. , 2014 .

[132]  K. Nemoto,et al.  Relationship Between Plasma Concentrations of Lamotrigine and Its Early Therapeutic Effect of Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder , 2014, Therapeutic drug monitoring.

[133]  M. Corcoran,et al.  Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial of Ascending Multiple Doses , 2014, Journal of clinical psychopharmacology.

[134]  Samir K. Gupta,et al.  Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects. , 2014, Clinical Therapeutics.

[135]  C. Hiemke,et al.  Influence of Concomitant Medications on the Total Clearance and the Risk for Supra-therapeutic Plasma Concentrations of Citalopram. A Population-Based Cohort Study , 2014, Pharmacopsychiatry.

[136]  A. Altamura,et al.  Clinical pharmacology of atypical antipsychotics: an update , 2014, EXCLI journal.

[137]  M. Meyer,et al.  Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. , 2014, Toxicology letters.

[138]  Sung-Wan Kim,et al.  Perinatal Use of Aripiprazole: Plasma Levels, Placental Transfer, and Child Outcome in 3 New Cases , 2014, Journal of clinical psychopharmacology.

[139]  M. Fava,et al.  Rare Copy Number Variation in Treatment-Resistant Major Depressive Disorder , 2014, Biological Psychiatry.

[140]  K. Nemoto,et al.  Effects of Genetic Polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia , 2014, Therapeutic drug monitoring.

[141]  L. Chan,et al.  Pharmacokinetic and Pharmacodynamic Drug Interactions with Ethanol (Alcohol) , 2014, Clinical Pharmacokinetics.

[142]  D. Spyker,et al.  Effect of Smoking on the Pharmacokinetics of Inhaled Loxapine , 2014, Therapeutic drug monitoring.

[143]  H. Gréen,et al.  Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases , 2014, The Pharmacogenomics Journal.

[144]  I. Cascorbi,et al.  Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance , 2014, Expert opinion on drug metabolism & toxicology.

[145]  C. S. Hendershot,et al.  Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds , 2014, Addiction Science & Clinical Practice.

[146]  E. Swart,et al.  Therapeutic Drug Monitoring by Dried Blood Spot: Progress to Date and Future Directions , 2014, Clinical Pharmacokinetics.

[147]  E. Češková The need to improve current psychopharmacotherapy before developing new drugs , 2014, Expert opinion on pharmacotherapy.

[148]  S. Preskorn,et al.  Lurasidone drug-drug interaction studies: a comprehensive review , 2014, Drug metabolism and drug interactions.

[149]  A. Cleton,et al.  Effect of carbamazepine on the pharmacokinetics of paliperidone extended‐release tablets at steady‐state , 2014, Clinical pharmacology in drug development.

[150]  D. Ochoa,et al.  Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers , 2014, Human psychopharmacology.

[151]  J. Lindh,et al.  Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis , 2014, Clinical Pharmacokinetics.

[152]  E. Bendas,et al.  Pharmaceutical and Pharmacokinetic Evaluation of a Novel Fast Dissolving Film Formulation of Flupentixol Dihydrochloride , 2014, AAPS PharmSciTech.

[153]  Josemir W Sander,et al.  Lacosamide Serum Concentrations in Adult Patients With Epilepsy: The Influence of Gender, Age, Dose, and Concomitant Antiepileptic Drugs , 2014, Therapeutic drug monitoring.

[154]  F. Sjöqvist Development of clinical pharmacology as a medical speciality in Europe - the roles of WHO, IUPHAR and EACPT. , 2014, Basic & clinical pharmacology & toxicology.

[155]  E. Palmer,et al.  Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. , 2014, The Annals of pharmacotherapy.

[156]  N. Yasui-Furukori,et al.  Therapeutic Reference Range for Plasma Concentrations of Paroxetine in Patients With Major Depressive Disorders , 2014, Therapeutic drug monitoring.

[157]  C. Hiemke,et al.  Serum Concentrations of Hydroxybupropion for Dose Optimization of Depressed Patients Treated With Bupropion , 2014, Therapeutic drug monitoring.

[158]  Volker Arolt,et al.  Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. , 2014, The international journal of neuropsychopharmacology.

[159]  D. Schaid,et al.  Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. , 2014, British Journal of Clinical Pharmacology.

[160]  J. Kane,et al.  Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study , 2014, British Journal of Psychiatry.

[161]  T. La Ferla,et al.  The pharmacokinetics of long-acting antipsychotic medications. , 2014, Current clinical pharmacology.

[162]  W. Myung,et al.  Therapeutic Drug Monitoring of Mirtazapine in a Routine Outpatient Setting in Asian Psychiatric Patients , 2014, Pharmacopsychiatry.

[163]  A. Płotka,et al.  Pregabalin Controlled-Release Pharmacokinetics in Healthy Volunteers: Analysis of Four Multiple-Dose Randomized Clinical Pharmacology Studies , 2014, Clinical Drug Investigation.

[164]  W. Daniel,et al.  The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application. , 2014, Biochemical pharmacology.

[165]  M. Ingelman-Sundberg,et al.  High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. , 2014, Omics : a journal of integrative biology.

[166]  Muriel Noetzli,et al.  Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. , 2014, British journal of clinical pharmacology.

[167]  G. Gründer,et al.  [Therapeutic drug monitoring in psychiatry. A brief summary of the new consensus paper by the task force on TDM of the AGNP]. , 2014, Der Nervenarzt.

[168]  A. Gasbarrini,et al.  Liquid Melevodopa Versus Standard Levodopa in Patients With Parkinson Disease and Small Intestinal Bacterial Overgrowth , 2014, Clinical neuropharmacology.

[169]  K. Carroll,et al.  Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management? , 2014, Drug and alcohol dependence.

[170]  C. Hiemke,et al.  Prediction of Antidepressant Response to Venlafaxine by a Combination of Early Response Assessment and Therapeutic Drug Monitoring , 2014, Pharmacopsychiatry.

[171]  A. Falcão,et al.  Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations , 2014, European Journal of Clinical Pharmacology.

[172]  Chuan-Yue Wang,et al.  Population Pharmacokinetic/Pharmacodynamic Model of Clozapine for Characterizing the Relationship Between Accumulated Exposure and PANSS Scores in Patients With Schizophrenia , 2014, Therapeutic drug monitoring.

[173]  J. Ferry,et al.  The practical impact of altered dosing on perampanel plasma concentrations: Pharmacokinetic modeling from clinical studies , 2014, Epilepsy & Behavior.

[174]  L. Lázaro,et al.  Plasma Fluoxetine Concentrations and Clinical Improvement in an Adolescent Sample Diagnosed With Major Depressive Disorder, Obsessive-Compulsive Disorder, or Generalized Anxiety Disorder , 2014, Journal of clinical psychopharmacology.

[175]  K. Nakagawa,et al.  Effects of CYP2C19 and P450 Oxidoreductase Polymorphisms on the Population Pharmacokinetics of Clobazam and N-Desmethylclobazam in Japanese Patients With Epilepsy , 2014, Therapeutic drug monitoring.

[176]  C. Eap,et al.  Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a nonfatal overdose during a suicide attempt. , 2014, Journal of clinical psychopharmacology.

[177]  J. Proost,et al.  Sex Differences in the Pharmacokinetics of Antidepressants: Influence of Female Sex Hormones and Oral Contraceptives , 2014, Clinical Pharmacokinetics.

[178]  H. Naik,et al.  Population Pharmacokinetic Meta-Analysis of Vortioxetine in Healthy Individuals , 2014, Basic & clinical pharmacology & toxicology.

[179]  L. Citrome Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism , 2014, Expert opinion on drug metabolism & toxicology.

[180]  C. Eap,et al.  [Pharmacokinetic alterations in pregnancy and use of therapeutic drug monitoring]. , 2014, Therapie.

[181]  C. Eap,et al.  [Pharmacokinetic alterations in pregnancy and use of therapeutic drug monitoring]. , 2014, Therapie.

[182]  T. Terao,et al.  Therapeutic Window of Lamotrigine for Mood Disorders: A Naturalistic Retrospective Study , 2014, Pharmacopsychiatry.

[183]  R. Beran,et al.  Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs) , 2014, Seizure.

[184]  C. Eap,et al.  Can Valproic Acid be an Inducer of Clozapine Metabolism? , 2014, Pharmacopsychiatry.

[185]  F. Schifano Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern? , 2014, CNS Drugs.

[186]  E. Clementi,et al.  A case of tinnitus induced by chlorpromazine in a pediatric patient , 2014, Journal of pharmacology & pharmacotherapeutics.

[187]  X. Jiang,et al.  Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers , 2014, Journal of clinical pharmacy and therapeutics.

[188]  W. Haefeli,et al.  Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan. , 2014, International journal of clinical pharmacology and therapeutics.

[189]  Reinhold Schmidt,et al.  Medication Adherence in Patients With Dementia: An Austrian Cohort Study , 2014, Alzheimer disease and associated disorders.

[190]  L. Bertilsson,et al.  Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients , 2014, European Journal of Clinical Pharmacology.

[191]  R. Siliciano,et al.  A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[192]  Mara R. Livezey,et al.  Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6 , 2014, Xenobiotica; the fate of foreign compounds in biological systems.

[193]  S. Preskorn Therapeutic Drug Monitoring (TDM) in Psychiatry (Part I): Why Studies Attempting to Correlate Drug Concentration and Antidepressant Response Don’t Work , 2014, Journal of psychiatric practice.

[194]  Pia Baldinger,et al.  Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET , 2014, NeuroImage.

[195]  C. Eap,et al.  Pharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring to Genomic Medicine , 2014, Clinical pharmacology and therapeutics.

[196]  Bernard Sabbe,et al.  High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[197]  P. Lahmek,et al.  Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis , 2014, PloS one.

[198]  P. Fischer,et al.  QTc Veränderungen bei intravenöser Akutsedierung mit Haloperidol, Prothipendyl und Lorazepam , 2014, neuropsychiatrie.

[199]  C. Jang,et al.  Effects of CYP2C19 Genetic Polymorphisms on Atomoxetine Pharmacokinetics , 2014, Journal of clinical psychopharmacology.

[200]  J. Kennedy,et al.  Pharmacogenetics of Antipsychotics , 2014, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[201]  M. Detke,et al.  Effects of Duloxetine on Norepinephrine and Serotonin Transporter Activity in Healthy Subjects , 2014, Journal of clinical psychopharmacology.

[202]  N. Cimino,et al.  Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review , 2014, Drug metabolism reviews.

[203]  A. Antonini,et al.  Novel levodopa formulations in the treatment of Parkinson's disease , 2014, Expert review of neurotherapeutics.

[204]  S. Dutta,et al.  Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets , 2014, British journal of clinical pharmacology.

[205]  T. Si,et al.  Pharmacokinetics and Tolerability of Extended-Release Quetiapine Fumarate in Han Chinese Patients with Schizophrenia , 2014, Clinical Pharmacokinetics.

[206]  J. Thome,et al.  Therapeutic Drug Monitoring of Zuclopenthixol in a Double-Blind Placebo-Controlled Discontinuation Study in Adults with Intellectual Disabilities and Aggressive Behaviour , 2013, Pharmacopsychiatry.

[207]  A. Verstraete,et al.  Comparison of drug concentrations between whole blood and oral fluid. , 2013, Drug testing and analysis.

[208]  B. Pollock,et al.  Therapeutic window for striatal dopamine D(2/3) receptor occupancy in older patients with schizophrenia: a pilot PET study. , 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[209]  M. Hammarlund-Udenaes Pharmacokinetic Concepts in Brain Drug Delivery , 2014 .

[210]  P. Riederer,et al.  SLC6A2 and SLC6A4 Variants interact with Venlafaxine Serum Concentrations to Influence Therapy Outcome , 2014, Pharmacopsychiatry.

[211]  J. Brockmöller,et al.  Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. , 2014, Pharmacology & therapeutics.

[212]  J. Scharfetter,et al.  [QTc prolongation induced by intravenous sedation with Haloperidol, Prothipendyl and Lorazepam]. , 2014, Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater.

[213]  E. McCance-Katz,et al.  Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals. , 2014, The American journal on addictions.

[214]  Zhu Rong-hua,et al.  Quantitative analysis of trazodone in human plasma by using HPLC-fluorescence detector coupled with strong cation exchange chromatographic column: application to a pharmacokinetic study in Chinese healthy volunteers. , 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[215]  S. Irie,et al.  Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype. , 2014, Drug metabolism and pharmacokinetics.

[216]  M. Mimura,et al.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. , 2014, Schizophrenia bulletin.

[217]  Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine , 2014, European Journal of Drug Metabolism and Pharmacokinetics.

[218]  A. Falcão,et al.  Effect of moderate liver impairment on the pharmacokinetics of opicapone , 2014, European Journal of Clinical Pharmacology.

[219]  Hayden B Bosworth,et al.  Ingredients of successful interventions to improve medication adherence. , 2013, JAMA.

[220]  G. Gründer,et al.  [Therapeutic drug monitoring in psychiatry. A brief summary of the new consensus paper by the task force on TDM of the AGNP]. , 2014, Der Nervenarzt.

[221]  M. Contin,et al.  Lacosamide Therapeutic Monitoring in Patients With Epilepsy: Effect of Concomitant Antiepileptic Drugs , 2013, Therapeutic drug monitoring.

[222]  Chuan-Yue Wang,et al.  Therapeutic Drug Monitoring of Psychotropic Drugs in China: A Nationwide Survey , 2013, Therapeutic Drug Monitoring.

[223]  H. Watanabe,et al.  Chronological Effects of Rifampicin Discontinuation on Cytochrome P450 Activity in Healthy Japanese Volunteers, Using the Cocktail Method , 2013, Clinical pharmacology and therapeutics.

[224]  D. Rujescu,et al.  Population Pharmacokinetic-Pharmacodynamic Modeling of Haloperidol in Patients With Schizophrenia Using Positive and Negative Syndrome Rating Scale , 2013, Journal of clinical psychopharmacology.

[225]  B. Miljković,et al.  Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[226]  G. Gründer,et al.  Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression , 2013, Expert review of neurotherapeutics.

[227]  D. Tompson,et al.  Clinical pharmacokinetics of retigabine/ezogabine. , 2013, Current clinical pharmacology.

[228]  Tim K Mackey,et al.  Improving global health governance to combat counterfeit medicines: a proposal for a UNODC-WHO-Interpol trilateral mechanism , 2013, BMC Medicine.

[229]  C. Halldin,et al.  5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects , 2013, European Neuropsychopharmacology.

[230]  Hilmar P. Sigurdsson,et al.  The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy , 2013, International review of psychiatry.

[231]  J. Kane,et al.  Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study , 2013, Schizophrenia Research.

[232]  T. Banaschewski,et al.  Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies , 2013, BMC Psychiatry.

[233]  M. Nitsche,et al.  Seizures during antidepressant treatment in psychiatric inpatients—results from the transnational pharmacovigilance project “Arzneimittelsicherheit in der Psychiatrie” (AMSP) 1993–2008 , 2013, Psychopharmacology.

[234]  A. Tadić,et al.  Early Improvement and Serum Concentrations of Citalopram to Predict Antidepressant Drug Response of Patients with Major Depression , 2013, Pharmacopsychiatry.

[235]  G. Laje Pharmacogenetics of mood disorders: what clinicians need to know , 2013, CNS Spectrums.

[236]  L. Citrome A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach , 2013, CNS Drugs.

[237]  S. Preskorn,et al.  Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open‐label, crossover studies , 2013, Human psychopharmacology.

[238]  V. Voříšek,et al.  Black Esophagus: Acute Esophageal Necrosis in Fatal Haloperidol Intoxication , 2013, Journal of forensic sciences.

[239]  P. Hubert,et al.  PLASMA LEVEL MONITORING OF THE MAJOR METABOLITES OF DIACETYLMORPHINE (HEROIN) BY THE “CHASING THE DRAGON” ROUTE IN SEVERE HEROIN ADDICTS , 2013, Acta clinica Belgica.

[240]  J. Buchbjerg,et al.  Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant , 2013, Clinical Drug Investigation.

[241]  N. Benowitz,et al.  Genetic and Pharmacokinetic Determinants of Response to Transdermal Nicotine in White, Black and Asian Non-Smokers , 2013, Clinical pharmacology and therapeutics.

[242]  A. Nobili,et al.  A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia , 2013, Therapeutics and clinical risk management.

[243]  J. Röschke,et al.  Quetiapine and Norquetiapine Serum Concentrations and Clinical Effects in Depressed Patients Under Augmentation Therapy With Quetiapine , 2013, Therapeutic drug monitoring.

[244]  J. A. Boer,et al.  ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder , 2012, The Pharmacogenomics Journal.

[245]  R. Grohmann,et al.  Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. , 2013, Swiss medical weekly.

[246]  O. Levran,et al.  CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction , 2013, Addiction biology.

[247]  P. Ihle,et al.  Prescribing potentially inappropriate medication (PIM) in Germany's elderly as indicated by the PRISCUS list. An analysis based on regional claims data , 2013, Pharmacoepidemiology and drug safety.

[248]  B. Larance,et al.  A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. , 2013, Drug and alcohol dependence.

[249]  Leonardo V. Lopez,et al.  Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: A review of the literature , 2013, Schizophrenia Research.

[250]  J. de Leon Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry , 2013, Acta Neuropsychiatrica.

[251]  A. Patat,et al.  An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. , 2013, Clinical therapeutics.

[252]  S. Handley,et al.  Plasma quetiapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2000–2011 , 2013, Therapeutic advances in psychopharmacology.

[253]  A. Jones,et al.  Concentrations of Diazepam and Nordiazepam in 1000 Blood Samples From Apprehended Drivers—Therapeutic Use or Abuse of Anxiolytics? , 2013, Journal of pharmacy practice.

[254]  J. Ramaekers,et al.  A Randomized Trial on the Acute and Steady‐State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition , 2013, Clinical pharmacology and therapeutics.

[255]  S. Kapur,et al.  Olanzapine: A Systematic Review and Meta-Regression of the Relationships Between Dose, Plasma Concentration, Receptor Occupancy, and Response , 2013, Journal of clinical psychopharmacology.

[256]  S. Seedat,et al.  Plasma, Oral Fluid, and Whole-Blood Distribution of Antipsychotics and Metabolites in Clinical Samples , 2013, Therapeutic drug monitoring.

[257]  Hidehiko Takahashi,et al.  Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2). , 2013, The international journal of neuropsychopharmacology.

[258]  Matthias J. Müller,et al.  Potential Cost-effectiveness of Therapeutic Drug Monitoring for Depressed Patients Treated With Citalopram , 2013, Therapeutic drug monitoring.

[259]  J. Ott,et al.  Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. , 2013, Pharmacogenomics.

[260]  T. Müller Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease: Focus on Levodopa/Carbidopa/Entacapone for Treatment of Levodopa-Associated Motor Complications , 2013, Clinical neuropharmacology.

[261]  Y. Sawada,et al.  Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. , 2013, International journal of clinical pharmacology and therapeutics.

[262]  Simon Handley,et al.  Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged <18 years: data from a therapeutic drug monitoring service, 1994–2010 , 2013, Early intervention in psychiatry.

[263]  J J Swen,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013, Clinical pharmacology and therapeutics.

[264]  S. Videla,et al.  Pharmacokinetic Dose Proportionality Between Two Strengths (12.5 mg and 25 mg) of Doxylamine Hydrogen Succinate Film-Coated Tablets in Fasting State: A Single-Dose, Randomized, Two-Period Crossover Study in Healthy Volunteers , 2013, Drugs in R&D.

[265]  M. Corcoran,et al.  Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate , 2013, Drugs in R&D.

[266]  P. Weiden,et al.  Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. , 2013, The Journal of clinical psychiatry.

[267]  Y. Daali,et al.  Applications of CYP450 Testing in the Clinical Setting , 2013, Molecular Diagnosis & Therapy.

[268]  C. Eap,et al.  Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high performance liquid chromatography tandem mass spectrometry. , 2013, Journal of pharmaceutical and biomedical analysis.

[269]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[270]  J. Verster,et al.  Blood drug concentrations of benzodiazepines correlate poorly with actual driving impairment. , 2013, Sleep medicine reviews.

[271]  E. Binder,et al.  Gene × environment interactions in the prediction of response to antidepressant treatment. , 2013, The international journal of neuropsychopharmacology.

[272]  Thomas Bürkle,et al.  Adverse drug events in older patients admitted as an emergency: the role of potentially inappropriate medication in elderly people (PRISCUS). , 2013, Deutsches Arzteblatt international.

[273]  K. Lasseter,et al.  An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in Healthy Adults , 2013, Clinical Drug Investigation.

[274]  A. Altamura,et al.  Understanding the pharmacokinetics of anxiolytic drugs , 2013, Expert opinion on drug metabolism & toxicology.

[275]  E. Corruble,et al.  [Recommendations for therapeutic monitoring of antidepressants]. , 2013, Revue medicale suisse.

[276]  J. Ahlner,et al.  A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. , 2013, Forensic science international.

[277]  P. Fusar-Poli,et al.  Antipsychotic drugs and breastfeeding. , 2013, Pediatric endocrinology reviews : PER.

[278]  T. Tomson,et al.  Antiepileptic drug treatment in pregnancy: Changes in drug disposition and their clinical implications , 2013, Epilepsia.

[279]  U. Lertxundi,et al.  Expert‐based drug lists to measure anticholinergic burden: similar names, different results , 2013, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society.

[280]  J. Brockmöller,et al.  Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function , 2013, Molecular Psychiatry.

[281]  Y. Okamoto,et al.  The valproate serum level in maintenance therapy for bipolar disorder in Japan. , 2013, Hiroshima journal of medical sciences.

[282]  M. Corcoran,et al.  Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release , 2013, Drugs in R&D.

[283]  J. Longstreth,et al.  Pharmacokinetics of Vilazodone in Patients with Mild or Moderate Renal Impairment , 2013, Clinical Drug Investigation.

[284]  J. Deckert,et al.  Elevated clozapine serum levels in combination with perazine , 2013, Psychopharmacology.

[285]  D. Marazziti,et al.  Pharmacokinetics and pharmacodinamics of psychotropic drugs: effect of sex , 2013, CNS Spectrums.

[286]  T. R. Johnson,et al.  Prediction of Crizotinib-Midazolam Interaction Using the Simcyp Population-Based Simulator: Comparison of CYP3A Time-Dependent Inhibition between Human Liver Microsomes versus Hepatocytes , 2013, Drug Metabolism and Disposition.

[287]  E. Spina,et al.  Clobazam Therapeutic Drug Monitoring: A Comprehensive Review of the Literature With Proposals to Improve Future Studies , 2013, Therapeutic drug monitoring.

[288]  Stephan Ripke,et al.  Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. , 2013, The American journal of psychiatry.

[289]  M. Gerlach,et al.  The Relation Between Dosage, Serum Concentrations, and Clinical Outcome in Children and Adolescents Treated With Sertraline: A Naturalistic Study , 2013, Therapeutic drug monitoring.

[290]  T. Lewander,et al.  Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers , 2013, Acta neurologica Scandinavica.

[291]  Muriel Noetzli,et al.  Population Pharmacokinetic Study of Memantine: Effects of Clinical and Genetic Factors , 2013, Clinical Pharmacokinetics.

[292]  P. Patsalos,et al.  Therapeutic Drug Monitoring of Antiepileptic Drugs by Use of Saliva , 2013, Therapeutic drug monitoring.

[293]  C. Hiemke,et al.  Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry. , 2013, Current drug delivery.

[294]  P. R. Montellano Cytochrome P450-activated prodrugs. , 2013 .

[295]  B. Wilffert,et al.  Influencing CYP Enzymes to Boost Psychiatric Treatment: A Review on Clinical Evidence , 2012, Pharmacopsychiatry.

[296]  P. Ortiz de Montellano Cytochrome P450-activated prodrugs , 2010 .

[297]  野上 毅 Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder : a positron emission tomography study with [¹¹C]DASB and (S,S)-[¹⁸F]FMeNER-D₂ , 2013 .

[298]  A. Jackson Impact of Release Mechanism on the Pharmacokinetic Performance of PAUC Metrics for Three Methylphenidate Products with Complex Absorption , 2013, Pharmaceutical Research.

[299]  W. Peñate,et al.  Risk factors for non-adherence to antidepressant treatment in patients with mood disorders , 2013, European Journal of Clinical Pharmacology.

[300]  P. Riederer,et al.  Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions , 2013, Journal of Neural Transmission.

[301]  D. Nyholm,et al.  Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients , 2013, The AAPS Journal.

[302]  C. Halldin,et al.  SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study , 2013, Psychopharmacology.

[303]  A. Iorio,et al.  Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale , 2013, Drugs & Aging.

[304]  K. Blennow,et al.  Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application , 2013, Alzheimer's Research & Therapy.

[305]  Jean-Pierre Michel,et al.  Evidence-Based Strategies for the Optimization of Pharmacotherapy in Older People , 2012, Drugs & Aging.

[306]  P. Jansen,et al.  Off-Label Prescribing in Older Patients , 2012, Drugs & Aging.

[307]  H. Neels,et al.  Therapeutic Drug Monitoring of Common Antipsychotics , 2012, Therapeutic drug monitoring.

[308]  Implementation of a Cost-Effective HPLC/UV Approach for Routine Medical Quantification of Memantine in Human Serum , 2012, Therapeutic drug monitoring.

[309]  E. Binder,et al.  Epigenetics, depression and antidepressant treatment. , 2012, Current pharmaceutical design.

[310]  V. Garg,et al.  Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin , 2012, Journal of clinical pharmacology.

[311]  N. Pageler,et al.  Significant Toxicity in a Young Female After Low-Dose Tricyclic Antidepressant Ingestion , 2012, Pediatric emergency care.

[312]  C. Eap,et al.  Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression , 2012, Journal of clinical psychopharmacology.

[313]  Pharmacokinetics and effect of food after oral administration of prolonged‐release tablets of ropinirole hydrochloride in Japanese patients with Parkinson’s disease , 2012, Journal of clinical pharmacy and therapeutics.

[314]  D. Matsui Therapeutic Drug Monitoring in Pregnancy , 2012, Therapeutic drug monitoring.

[315]  I. Zineh,et al.  CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations. , 2012, The Journal of clinical psychiatry.

[316]  T. Iwatsubo,et al.  Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood–brain barrier , 2012, Biopharmaceutics & drug disposition.

[317]  G. Stalla,et al.  Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. , 2012, European journal of endocrinology.

[318]  S. Handley,et al.  Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002–2010 , 2012, Human psychopharmacology.

[319]  Fanying Li,et al.  Excretion and Metabolism of Milnacipran in Humans after Oral Administration of Milnacipran Hydrochloride , 2012, Drug Metabolism and Disposition.

[320]  A. Altamura,et al.  Effect of Quetiapine and Norquetiapine on Anxiety and Depression in Major Psychoses Using a Pharmacokinetic Approach , 2012, Clinical Drug Investigation.

[321]  M. Schulz,et al.  Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics , 2012, Critical Care.

[322]  D. Bentué-Ferrer,et al.  Suivi thérapeutique pharmacologique de l’éthosuximide , 2012 .

[323]  L. Alphs,et al.  Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. , 2012, Innovations in clinical neuroscience.

[324]  D. Fisher,et al.  Plasma Concentrations of Quetiapine, N-Desalkylquetiapine, O-Desalkylquetiapine, 7-Hydroxyquetiapine, and Quetiapine Sulfoxide in Relation to Quetiapine Dose, Formulation, and Other Factors , 2012, Therapeutic drug monitoring.

[325]  B. Bang-Andersen,et al.  Identification of the Cytochrome P450 and Other Enzymes Involved in the In Vitro Oxidative Metabolism of a Novel Antidepressant, Lu AA21004 , 2012, Drug Metabolism and Disposition.

[326]  B. Langguth,et al.  Hypothermia Associated With Antipsychotic Drug Use: A Clinical Case Series and Review of Current Literature , 2012, Journal of clinical pharmacology.

[327]  H. Derendorf,et al.  Population pharmacokinetics of steady‐state carbamazepine in Egyptian epilepsy patients , 2012, Journal of clinical pharmacy and therapeutics.

[328]  A. Bond,et al.  After the randomised injectable opiate treatment trial: post-trial investigation of slow-release oral morphine as an alternative opiate maintenance medication. , 2012, Drug and alcohol review.

[329]  C. Noe,et al.  Blood-brain barrier in vitro models as tools in drug discovery: assessment of the transport ranking of antihistaminic drugs. , 2012, Die Pharmazie.

[330]  S. Dubovsky,et al.  Short‐term safety and pharmacokinetic profile of asenapine in older patients with psychosis , 2012, International journal of geriatric psychiatry.

[331]  R. González-Sarmiento,et al.  Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis , 2012, Addiction biology.

[332]  E. Sellers,et al.  Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. , 2012, Clinical therapeutics.

[333]  Guang-Ji Wang,et al.  Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients , 2012, European Journal of Clinical Pharmacology.

[334]  C. Hiemke,et al.  Flupentixol: relevance of stereoselective therapeutic drug monitoring , 2012, Psychopharmacology.

[335]  F. Riquier,,et al.  Adherence to Antidepressant Treatment: What the Doctor Thinks and What the Patient Says , 2012, Pharmacopsychiatry.

[336]  C. Campanelli American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults , 2012 .

[337]  Jae Sung Lee,et al.  Predicting Brain Occupancy from Plasma Levels using PET: Superiority of Combining Pharmacokinetics with Pharmacodynamics while Modeling the Relationship , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[338]  B. Søgaard,et al.  Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. , 2012, Basic & clinical pharmacology & toxicology.

[339]  K. Monostory,et al.  Estimation of Drug-Metabolizing Capacity by Cytochrome P450 Genotyping and Expression , 2012, Journal of Pharmacology and Experimental Therapeutics.

[340]  M. Raggi,et al.  Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. , 2012, Current medicinal chemistry.

[341]  E. Rosenthal,et al.  Process Improvement Methods Increase the Efficiency, Accuracy, and Utility of a Neurocritical Care Research Repository , 2012, Neurocritical Care.

[342]  D. Bentué-Ferrer,et al.  Suivi thérapeutique pharmacologique du rufinamide , 2012 .

[343]  D. Bentué-Ferrer,et al.  Suivi thérapeutique pharmacologique du lacosamide , 2012 .

[344]  M. Gerlach,et al.  Therapeutic Drug Monitoring of Children and Adolescents Treated with Fluoxetine , 2011, Pharmacopsychiatry.

[345]  M. Rietschel,et al.  CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP , 2012, Journal of psychopharmacology.

[346]  C. Eap,et al.  Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography-electrospray mass spectrometry for therapeutic drug monitoring. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[347]  L. Pani,et al.  Subthreshold depression in older subjects: An unmet therapeutic need , 2012, The Journal of Nutrition, Health & Aging.

[348]  R. Grohmann,et al.  Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. , 2012, Journal of affective disorders.

[349]  M. Contin,et al.  Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy , 2012, Epilepsy Research.

[350]  Implementation of a cost-effective HPLC/UV-approach for medical routine quantification of donepezil in human serum. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[351]  M. Rudorfer Monitoring Tricyclic Antidepressant Therapy , 1992, PharmacoEconomics.

[352]  M. Mattila,et al.  Flunitrazepam: A Review of its Pharmacological Properties and Therapeutic Use , 1980, Drugs.

[353]  S. Preskorn,et al.  Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP 2 D 6 Extensive and Poor Metabolizers A Randomized , Open-Label , Two-Period , Parallel-Group , Crossover Study , 2012 .

[354]  M. Verdier,et al.  [Therapeutic drug monitoring of rufinamide]. , 2012, Therapie.

[355]  M. Verdier,et al.  [Therapeutic drug monitoring of lacosamide]. , 2012, Therapie.

[356]  Ulrich M. Zanger,et al.  Metabolism of drugs and other xenobiotics , 2012 .

[357]  K. Arumugam,et al.  Population pharmacokinetics of lamotrigine in Indian epileptic patients , 2012, European Journal of Clinical Pharmacology.

[358]  Matthias J. Müller,et al.  AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. , 2014, Pharmacopsychiatry.

[359]  G. Ranzani,et al.  Morphine metabolism, transport and brain disposition , 2011, Metabolic Brain Disease.

[360]  N. Yasui-Furukori,et al.  Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders , 2011, Human psychopharmacology.

[361]  Yu-Li Liu,et al.  Aripiprazole and Dehydroaripiprazole Plasma Concentrations and Clinical Responses in Patients With Schizophrenia , 2011, Journal of clinical psychopharmacology.

[362]  Yuichi Sugiyama,et al.  Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate , 2011, Journal of Pharmacology and Experimental Therapeutics.

[363]  L. Brandt,et al.  Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder , 2011, Schizophrenia Research.

[364]  J. Lieberman,et al.  Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study , 2011, Journal of clinical pharmacology.

[365]  A. Rostami-Hodjegan,et al.  The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel , 2011, Drug Metabolism and Disposition.

[366]  K. G. Jensen,et al.  Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[367]  K. Midha,et al.  In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine , 2011, Biopharmaceutics & drug disposition.

[368]  J. V. van Gerven,et al.  The perception and pharmacokinetics of a 20-mg dose of escitalopram orodispersible tablets in a relative bioavailability study in healthy men. , 2011, Clinical therapeutics.

[369]  U. Stephani,et al.  Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy , 2011, Pharmacogenetics and genomics.

[370]  Hannu Raunio,et al.  Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.

[371]  E. Haen Therapeutic Drug Monitoring in Pharmacovigilance and Pharmacotherapy Safety , 2011, Pharmacopsychiatry.

[372]  C. Hiemke,et al.  Therapeutic Drug Monitoring for Drugs Used in the Treatment of Substance-Related Disorders: Literature Review Using a Therapeutic Drug Monitoring Appropriateness Rating Scale , 2011, Therapeutic drug monitoring.

[373]  M. Pastore,et al.  Therapeutic Drug Monitoring in Italian Psychiatry , 2011, Pharmacopsychiatry.

[374]  P. Lazarus,et al.  Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants , 2011, Pharmacogenetics and genomics.

[375]  M. Gerlach,et al.  Therapeutic Drug Monitoring in Child and Adolescent Psychiatry , 2011, Pharmacopsychiatry.

[376]  J. Deckert,et al.  No Influence of Body Weight on Serum Levels of Antidepressants , 2011, Therapeutic drug monitoring.

[377]  G. Gründer,et al.  Therapeutic Plasma Concentrations of Antidepressants and Antipsychotics: Lessons from PET Imaging , 2011, Pharmacopsychiatry.

[378]  D. Rujescu,et al.  Predicting Response to Psychopharmacological Treatment: Survey of Recent Results , 2011, Pharmacopsychiatry.

[379]  Matthias J. Müller,et al.  AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. , 2014, Pharmacopsychiatry.

[380]  W. Löscher,et al.  Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. , 2011, Current pharmaceutical design.

[381]  F. McMahon,et al.  Genome-wide association studies of antidepressant outcome: A brief review , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[382]  C. Brandt,et al.  Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions – First clinical experience , 2011, Epilepsy Research.

[383]  V. Gribkoff,et al.  Safety, Tolerability, and Pharmacokinetics of KNS‐760704 (Dexpramipexole) in Healthy Adult Subjects , 2011, Journal of clinical pharmacology.

[384]  M. Levine,et al.  Cardiotoxicity and Serotonin Syndrome Complicating a Milnacipran Overdose , 2011, Journal of Medical Toxicology.

[385]  J. Kehr,et al.  Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study , 2011, Journal of psychopharmacology.

[386]  E. Lunell,et al.  Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum. , 2011, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[387]  Ji-Young Park,et al.  Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study. , 2011, Clinical therapeutics.

[388]  Suneel K. Gupta,et al.  Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder. , 2011, Journal of child and adolescent psychopharmacology.

[389]  A. Collier,et al.  Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir , 2011, Drug Metabolism and Disposition.

[390]  Matthias J. Müller,et al.  Association Between Citalopram Serum Levels and Clinical Improvement of Patients With Major Depression , 2011, Journal of clinical psychopharmacology.

[391]  S. Curry,et al.  Prolonged Toxicity after Amitriptyline Overdose in a Patient Deficient in CYP2D6 Activity , 2011, Journal of Medical Toxicology.

[392]  G. Zernig,et al.  “There is no dose–response relationship in psychopharmacotherapy” vs “pharmacotherapy in psychiatry is based on ligand–receptor interaction”: a unifying hypothesis and the need for plasma concentration based clinical trials , 2011, Psychopharmacology.

[393]  B. Miljković,et al.  Evaluation of Single‐Point Sampling Strategies for the Estimation of Moclobemide Exposure in Depressive Patients , 2011, Journal of clinical pharmacology.

[394]  Hans H Stassen,et al.  Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. , 2011, Journal of affective disorders.

[395]  T. Hasunuma,et al.  Single‐ and Multiple‐Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Japanese Adult Smokers , 2011, Journal of clinical pharmacology.

[396]  B. Pollock,et al.  Genetic Variation in CYP3A43 Explains Racial Difference in Olanzapine Clearance , 2011, Molecular Psychiatry.

[397]  P. Neuvonen,et al.  Itraconazole, a P‐Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin‐Inhibiting Effect of Aliskiren , 2011, Journal of clinical pharmacology.

[398]  Stefano Zamuner,et al.  Prediction of Repeat-Dose Occupancy from Single-Dose Data: Characterisation of the Relationship between Plasma Pharmacokinetics and Brain Target Occupancy , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[399]  H. Refsum,et al.  Pharmacokinetic Variability of Quetiapine and the Active Metabolite N-desalkylquetiapine in Psychiatric Patients , 2011, Therapeutic drug monitoring.

[400]  W. Tong,et al.  Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor , 2011, Drug Metabolism and Disposition.

[401]  C. Frei,et al.  Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[402]  U. Preuss,et al.  Quetiapine in Adolescents with Non-Affective Psychotic Disorders: An Open-Label Trial , 2011, Pharmacopsychiatry.

[403]  J. Biernacka,et al.  Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine , 2011, Therapeutic drug monitoring.

[404]  P. K. Gillman Advances Pertaining to the Pharmacology and Interactions of Irreversible Nonselective Monoamine Oxidase Inhibitors , 2011, Journal of clinical psychopharmacology.

[405]  B. Corrigan,et al.  Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures , 2011, Epilepsia.

[406]  N. Ryan,et al.  Antidepressant Exposure as a Predictor of Clinical Outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) Study , 2011, Journal of clinical psychopharmacology.

[407]  N. Kokras,et al.  Sex differences in pharmacokinetics of antidepressants , 2011, Expert opinion on drug metabolism & toxicology.

[408]  H. Silver,et al.  Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. , 2011, Pharmacopsychiatry.

[409]  E. V. van Roon,et al.  Coma After Overdose with Duloxetine , 2011, The Annals of pharmacotherapy.

[410]  A. Topiwala,et al.  The pharmacological management of violence in schizophrenia: a structured review , 2011, Expert review of neurotherapeutics.

[411]  N. Cutler,et al.  The impact of gender on antidepressants. , 2011, Current topics in behavioral neurosciences.

[412]  M. Thase,et al.  The clinical management of bipolar disorder: a review of evidence-based guidelines. , 2011, The primary care companion for CNS disorders.

[413]  J. Wilimowska,et al.  [Sulpiride poisoning--case report confirmed with the quantitative determination of the xenobiotic serum level]. , 2011, Przeglad lekarski.

[414]  S. Preskorn,et al.  Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP2D6 Extensive and Poor Metabolizers , 2011, Clinical drug investigation.

[415]  O. Spigset,et al.  Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies , 2010, Acta psychiatrica Scandinavica.

[416]  Partial compliance as determined from plasma levels of sertraline and its metabolite in depressed patients in primary care. , 2010, Journal of clinical psychopharmacology.

[417]  P. Weiden,et al.  Measurement of psychiatric treatment adherence. , 2010, Journal of psychosomatic research.

[418]  N. Siva Tackling the booming trade in counterfeit drugs , 2010, The Lancet.

[419]  M. Contin,et al.  Pharmacokinetics of levodopa , 2010, Journal of Neurology.

[420]  Peng Wenxing,et al.  In vitro and in vivo evaluation of the effects of duloxetine on P‐gp function , 2010, Human psychopharmacology.

[421]  M. Uhr,et al.  Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice , 2010, Neuropharmacology.

[422]  S. Preskorn CNS drug development – Phase III , 2010 .

[423]  S. Preskorn CNS drug development: Part II: Advances from the 1960s to the 1990s. , 2010, Journal of psychiatric practice.

[424]  W. Daniel,et al.  Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. , 2010, Biochemical pharmacology.

[425]  T. Barnes,et al.  Standards of lithium monitoring in mental health trusts in the UK , 2010, BMC psychiatry.

[426]  A. Mrhar,et al.  A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[427]  J. Kehr,et al.  Quetiapine and Norquetiapine in Plasma and Cerebrospinal Fluid of Schizophrenic Patients Treated With Quetiapine: Correlations to Clinical Outcome and HVA, 5-HIAA, and MHPG in CSF , 2010, Journal of clinical psychopharmacology.

[428]  E. P. Spencer,et al.  Plasma Clozapine and Norclozapine in Patients Prescribed Different Brands of Clozapine (Clozaril, Denzapine, and Zaponex) , 2010, Therapeutic drug monitoring.

[429]  Raymond Miller,et al.  A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin , 2010, Clinical pharmacokinetics.

[430]  Z. Bhagwagar,et al.  Antidepressant Response and the Serotonin Transporter Gene-Linked Polymorphic Region , 2010, Biological Psychiatry.

[431]  S. Preskorn CNS drug development. Part I: The early period of CNS drugs. , 2010, Journal of psychiatric practice.

[432]  T. Jeitner,et al.  ONCE‐DAILY MEMANTINE: PHARMACOKINETIC AND CLINICAL CONSIDERATIONS , 2010, Journal of the American Geriatrics Society.

[433]  D. Pounder,et al.  OPRM1 and CYP2B6 Gene Variants as Risk Factors in Methadone‐Related Deaths , 2010, Clinical pharmacology and therapeutics.

[434]  Hea‐Young Cho,et al.  Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects , 2010, Neuroscience.

[435]  L. Lazzeroni,et al.  ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression , 2010, Pharmacogenetics and genomics.

[436]  M. Reid,et al.  Acamprosate Determinations in Plasma and Cerebrospinal Fluid After Multiple Dosing Measured by Liquid Chromatography–Mass Spectroscopy: A Pharmacokinetic Study in Healthy Volunteers , 2010, Therapeutic drug monitoring.

[437]  Lewis Couchman,et al.  Plasma Clozapine, Norclozapine, and the Clozapine:Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1993–2007 , 2010, Therapeutic drug monitoring.

[438]  Sven Schmiedl,et al.  Potentially inappropriate medications in the elderly: the PRISCUS list. , 2010, Deutsches Arzteblatt international.

[439]  Paul Cumming,et al.  Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. , 2010, The international journal of neuropsychopharmacology.

[440]  A. Cleton,et al.  A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia , 2010, Journal of psychopharmacology.

[441]  A. Suzuki,et al.  Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients , 2010, Journal of psychopharmacology.

[442]  J. Lindenmayer Long-acting injectable antipsychotics: focus on olanzapine pamoate , 2010, Neuropsychiatric disease and treatment.

[443]  Q. Xiang,et al.  Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety , 2010, Journal of clinical pharmacology.

[444]  L. Wienkers,et al.  Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation , 2010, Drug Metabolism and Disposition.

[445]  S. Kapur,et al.  A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. , 2010, The Journal of clinical psychiatry.

[446]  J. Urquhart,et al.  [Compliance, concordance, adherence]. , 2010, Therapeutische Umschau. Revue therapeutique.

[447]  C. Hiemke,et al.  [Pharmacogenetics, therapeutic drug monitoring and non compliance]. , 2010, Therapeutische Umschau. Revue therapeutique.

[448]  E. Corruble,et al.  French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs , 2010, Fundamental & clinical pharmacology.

[449]  R. Perlis,et al.  Failure to Replicate Genetic Associations with Antidepressant Treatment Response in Duloxetine-Treated Patients , 2010, Biological Psychiatry.

[450]  K. Deligiannidis Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium. , 2010, The Journal of clinical psychiatry.

[451]  H. Hampel,et al.  Optimal management of Alzheimer’s disease patients: Clinical guidelines and family advice , 2010 .

[452]  S. Cichon,et al.  The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. , 2010, Neuropsychobiology.

[453]  N. Srinivas,et al.  Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine , 2010, European Journal of Clinical Pharmacology.

[454]  L. Tan,et al.  The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients , 2010, Clinical Neurology and Neurosurgery.

[455]  K. Safranow,et al.  Pharmacokinetic-Pharmacodynamic Modeling of Levodopa in Patients With Advanced Parkinson Disease , 2010, Clinical neuropharmacology.

[456]  Hongyu Yuan,et al.  Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers , 2010, European Journal of Clinical Pharmacology.

[457]  H. Hamer,et al.  Lacosamide intoxication in attempted suicide , 2010, Epilepsy & Behavior.

[458]  M. Schwarz,et al.  Serum concentrations of paliperidone versus risperidone and clinical effects , 2010, European Journal of Clinical Pharmacology.

[459]  Yu-Li Liu,et al.  Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. , 2010, Pharmacogenomics.

[460]  C. Eap,et al.  Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. , 2010, Archives of internal medicine.

[461]  K. G. Jensen,et al.  Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-Based Simulator , 2010, Drug Metabolism and Disposition.

[462]  T. Suhara,et al.  Estimation of Plasma IC50 of Donepezil for Cerebral Acetylcholinesterase Inhibition in Patients With Alzheimer Disease Using Positron Emission Tomography , 2010, Clinical neuropharmacology.

[463]  M. Gerlach,et al.  Serum Concentrations, Therapeutic Response and Side Effects in Children and Adolescents with Impulsive-Aggressive Symptoms during Risperidone Therapy , 2009, Pharmacopsychiatry.

[464]  R. Orlando,et al.  Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. , 2010, British journal of clinical pharmacology.

[465]  M. Kennedy Post‐mortem drug concentrations , 2010, Internal medicine journal.

[466]  D. Mrazek Psychiatric pharmacogenomic testing in clinical practice , 2010, Dialogues in clinical neuroscience.

[467]  A. Nobili,et al.  New atypical antipsychotics for schizophrenia: iloperidone , 2010, Drug design, development and therapy.

[468]  M. Sabbatini,et al.  Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient , 2010, Journal of clinical pharmacy and therapeutics.

[469]  S. Yamada,et al.  Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. , 2010, Biological & pharmaceutical bulletin.

[470]  M. H. Ensom,et al.  Does Valproic Acid Warrant Therapeutic Drug Monitoring in Bipolar Affective Disorder? , 2010, Therapeutic drug monitoring.

[471]  J. Stark,et al.  Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. , 2010, Clinical therapeutics.

[472]  A. Borobia,et al.  Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. , 2010, European journal of pharmacology.

[473]  M. Court Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system , 2010, Drug metabolism reviews.

[474]  D. Kupfer,et al.  Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure , 2010, Journal of clinical pharmacology.

[475]  J. Lieberman,et al.  Population Pharmacokinetics of Perphenazine in Schizophrenia Patients From CATIE: Impact of Race and Smoking , 2010, Journal of clinical pharmacology.

[476]  P. Weiden,et al.  Assessment of Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations from the Expert Consensus Guidelines , 2010, Journal of psychiatric practice.

[477]  Darin D Dougherty,et al.  A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. , 2009, International journal of molecular medicine.

[478]  L. Citrome Paliperidone palmitate – review of the efficacy, safety and cost of a new second‐generation depot antipsychotic medication , 2009, International journal of clinical practice.

[479]  C. Puozzo,et al.  Pharmacokinetics of milnacipran in renal impairment , 1998, European Journal of Drug Metabolism and Pharmacokinetics.

[480]  Hao Chen,et al.  Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy. , 2010, Chemical research in toxicology.

[481]  J. de Leon,et al.  The pharmacokinetics of paliperidone versus risperidone. , 2010, Psychosomatics.

[482]  F. Hässler,et al.  Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature. , 2010, Developmental disabilities research reviews.

[483]  J. N. van den Anker Developmental pharmacology. , 2010, Developmental disabilities research reviews.

[484]  G. Vinçon,et al.  Pharmacokinetics of milnacipran in liver impairment , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[485]  M. Hümpel,et al.  Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[486]  P. Sáiz,et al.  Association study of serotonergic gene variants with antipsychotic-induced adverse reactions , 2009, Psychiatric genetics.

[487]  S. Kapur,et al.  Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring , 2009, Acta psychiatrica Scandinavica.

[488]  J. Gádoros,et al.  Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD , 2009, Neuropharmacology.

[489]  T. Richards,et al.  Quantification of a Methadone Metabolite (EDDP) in Urine: Assessment of Compliance , 2009, Clinical Medicine & Research.

[490]  T. Tensfeldt,et al.  Population pharmacokinetic analysis of varenicline in adult smokers. , 2009, British journal of clinical pharmacology.

[491]  S. Preskorn,et al.  Exposure‐Response Analysis in Patients With Schizophrenia to Assess the Effect of Asenapine on QTc Prolongation , 2009, Journal of clinical pharmacology.

[492]  S. Preskorn Patients who do not respond to the "usual" dose: why Terry fell off the dose-response curve. , 2009, Journal of psychiatric practice.

[493]  P. Jenner,et al.  Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. , 2009, Clinical therapeutics.

[494]  David Taylor Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review , 2009, British Journal of Psychiatry.

[495]  J. Licinio,et al.  Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans , 2009, Molecular Psychiatry.

[496]  B. Wen,et al.  Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s. , 2009, Chemico-biological interactions.

[497]  W. Cawello,et al.  Absorption, Disposition, Metabolic Fate, and Elimination of the Dopamine Agonist Rotigotine in Man: Administration by Intravenous Infusion or Transdermal Delivery , 2009, Drug Metabolism and Disposition.

[498]  K. Kim,et al.  Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady‐state in Korean epileptic patients , 2009, Journal of clinical pharmacy and therapeutics.

[499]  P. Jacqmin,et al.  Pharmacokinetic/Pharmacodynamic Modeling of Psychomotor Impairment Induced by Oral Clonazepam in Healthy Volunteers , 2009, Therapeutic drug monitoring.

[500]  A. Parkinson,et al.  In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran , 2009, Drug Metabolism and Disposition.

[501]  P. Trzepacz,et al.  Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder , 2009, Attention deficit and hyperactivity disorders.

[502]  Susanne Winiwarter,et al.  Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. , 2009, Journal of medicinal chemistry.

[503]  W. Daniel,et al.  Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism — an in vitro study , 2009, Pharmacological reports : PR.

[504]  E. McCance-Katz,et al.  The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. , 2009, Basic & clinical pharmacology & toxicology.

[505]  R. Chadda,et al.  Therapeutic Drug Monitoring of Lithium in Patients With Bipolar Affective Disorder: Experiences From a Tertiary Care Hospital in India , 2009, American Journal of Therapeutics.

[506]  D. Addington Best practices: improving quality of care for patients with first-episode psychosis. , 2009, Psychiatric services.

[507]  B. Pfuhlmann,et al.  Duloxetine Serum Concentrations and Clinical Effects. Data from a Therapeutic Drug Monitoring (TDM) Survey , 2009, Pharmacopsychiatry.

[508]  I. Whyte,et al.  Clinical and ECG effects of escitalopram overdose. , 2009, Annals of emergency medicine.

[509]  C. Eap,et al.  ABCB1 and Cytochrome P450 Polymorphisms: Clinical Pharmacogenetics of Clozapine , 2009, Journal of clinical psychopharmacology.

[510]  J. Attia,et al.  Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study , 2009, European Journal of Clinical Pharmacology.

[511]  J. Watelet,et al.  Drug metabolism and pharmacokinetics , 2009, Drug metabolism reviews.

[512]  J. Watelet,et al.  Pharmacokinetics in special populations , 2009, Drug metabolism reviews.

[513]  P. Blier,et al.  Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. , 2009, The Journal of clinical psychiatry.

[514]  D. Jennings,et al.  Pharmacokinetic‐pharmacodynamic crossover comparison of two levodopa extension strategies , 2009, Movement disorders : official journal of the Movement Disorder Society.

[515]  Nirbhay N. Singh,et al.  Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. , 2009, Research in developmental disabilities.

[516]  Silas W Smith Chiral toxicology: it's the same thing...only different. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[517]  Cheryl F. Lichti,et al.  Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids , 2009, Drug Metabolism and Disposition.

[518]  J. Lötsch,et al.  Cytochrome P450 3A Inhibition by Atazanavir and Ritonavir, but Not Demography or Drug Formulation, Influences Saquinavir Population Pharmacokinetics in Human Immunodeficiency Virus Type 1-Infected Adults , 2009, Antimicrobial Agents and Chemotherapy.

[519]  M. Farré,et al.  Pharmacokinetics and Therapeutic Drug Monitoring of Psychotropic Drugs in Pediatrics , 2009, Therapeutic drug monitoring.

[520]  M. Nomoto,et al.  Plasma amantadine concentrations in patients with Parkinson's disease. , 2009, Parkinsonism & related disorders.

[521]  P. Mersch,et al.  Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: a naturalistic follow-up study. , 2009, Bipolar disorders.

[522]  L. Citrome,et al.  Olanzapine Plasma Concentrations After Treatment With 10, 20, and 40 mg/d in Patients With Schizophrenia: An Analysis of Correlations With Efficacy, Weight Gain, and Prolactin Concentration , 2009, Journal of Clinical Psychopharmacology.

[523]  N. Hakooz Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities. , 2009, Current drug metabolism.

[524]  Ulrich Klotz,et al.  Pharmacokinetics and drug metabolism in the elderly , 2009, Drug metabolism reviews.

[525]  C. Hiemke,et al.  Empfehlungen für die gutachterliche Bewertung von Medikamentenspiegeln in der Psychiatrie im gerichtsanhängigen Schadensfall , 2009 .

[526]  Shufeng Zhou,et al.  Polymorphism of human cytochrome P450 enzymes and its clinical impact , 2009, Drug metabolism reviews.

[527]  C. Hiemke,et al.  Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder , 2009, Journal of psychopharmacology.

[528]  E. Kornetova,et al.  Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[529]  M. Gerlach,et al.  Child and Adolescent Psychiatry and Mental Health Drug Monitoring in Child and Adolescent Psychiatry for Improved Efficacy and Safety of Psychopharmacotherapy , 2022 .

[530]  H. Refsum,et al.  Influence of Comedication on Serum Concentrations of Aripiprazole and Dehydroaripiprazole , 2009, Therapeutic drug monitoring.

[531]  Y. Liu,et al.  A simplified method to determine five cytochrome p450 probe drugs by HPLC in a single run. , 2009, Biological & pharmaceutical bulletin.

[532]  G. Gründer,et al.  The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey , 2009, European Psychiatry.

[533]  D. Lancet,et al.  Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3′-untranslated region , 2009, The Pharmacogenomics Journal.

[534]  G. Lefèvre,et al.  Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch , 2009, Journal of clinical pharmacology.

[535]  M. Reid,et al.  The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial , 2009, Psychopharmacology.

[536]  O. Brørs,et al.  O-demethylation of codeine to morphine inhibited by low-dose levomepromazine , 2009, European Journal of Clinical Pharmacology.

[537]  M. Brecher,et al.  Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[538]  Hans H Stassen,et al.  Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. , 2009, The Journal of clinical psychiatry.

[539]  N. Bergemann,et al.  Therapeutisches Drug-Monitoring von Psychopharmaka in der Schwangerschaft , 2009 .

[540]  B. Pollock,et al.  Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. , 2009, The Journal of clinical psychiatry.

[541]  A. Carlsson,et al.  The 'atypicality' of antipsychotics: a concept re-examined and re-defined , 2009, Nature Reviews Drug Discovery.

[542]  M. Seiberling,et al.  Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. , 2009, Clinical therapeutics.

[543]  H. Refsum,et al.  Metabolism of Quetiapine by CYP3A4 and CYP3A5 in Presence or Absence of Cytochrome B5 , 2009, Drug Metabolism and Disposition.

[544]  O. Spigset,et al.  Serum Concentrations of Antidepressant Drugs in a Naturalistic Setting: Compilation Based on a Large Therapeutic Drug Monitoring Database , 2009, Therapeutic drug monitoring.

[545]  D. Kupfer,et al.  The Effect of Reporting Methods for Dosing Times on the Estimation of Pharmacokinetic Parameters of Escitalopram , 2009, Journal of clinical pharmacology.

[546]  S. Preskorn,et al.  Comparison of the Pharmacokinetics of Venlafaxine Extended Release and Desvenlafaxine in Extensive and Poor Cytochrome P450 2D6 Metabolizers , 2009, Journal of clinical psychopharmacology.

[547]  Yuan-Han Yang,et al.  Simultaneous determination of galantamine, rivastigmine and NAP 226‐90 in plasma by MEKC and its application in Alzheimer's disease , 2009, Electrophoresis.

[548]  L. James Willmore,et al.  Vigabatrin: 2008 Update , 2009, Epilepsia.

[549]  K. Bala,et al.  Therapeutic Drug Monitoring: Appropriateness and Clinical Utility in Neuropsychiatry Practice , 2009, American journal of therapeutics.

[550]  T. Litovitz,et al.  Suicidal antidepressant overdoses: A comparative analysis by antidepressant type , 2008, Journal of Medical Toxicology.

[551]  H. Spiller,et al.  A fatal case of venlafaxine overdose , 2008, Journal of Medical Toxicology.

[552]  T. Egberts,et al.  Effect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations during Pregnancy , 2009, Clinical pharmacokinetics.

[553]  J. Ahlner,et al.  Steady-State Concentrations of Mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and their Enantiomers in Relation to Cytochrome P450 2D6 Genotype, Age and Smoking Behaviour , 2009, Clinical pharmacokinetics.

[554]  M. Heathman,et al.  Erratum to: Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation , 2009 .

[555]  D. Rujescu,et al.  Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. , 2009, Pharmacogenetics and genomics.

[556]  Shufeng Zhou Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.

[557]  D. Mattison,et al.  Sex Differences in Pharmacokinetics and Pharmacodynamics , 2009, Clinical pharmacokinetics.

[558]  G. Keating,et al.  Atomoxetine , 2009, Paediatric drugs.

[559]  Z. Todorović,et al.  Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. , 2009, Journal of pharmacological sciences.

[560]  J. Aubry,et al.  Lithium: Updated Human Knowledge Using an Evidence-Based Approach , 2009, CNS drugs.

[561]  V. Natarajan,et al.  Efavirenz Induces CYP2B6-Mediated Hydroxylation of Bupropion in Healthy Subjects , 2008, Journal of acquired immune deficiency syndromes.

[562]  D. Taylor Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety , 2008, Acta psychiatrica Scandinavica.

[563]  J. Kwon,et al.  Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. , 2008, British journal of clinical pharmacology.

[564]  Melinda F. Davis,et al.  Pharmacokinetics of Sertraline Across Pregnancy and Postpartum , 2008, Journal of clinical psychopharmacology.

[565]  J. Ahlner,et al.  Therapeutic Drug Monitoring of Ziprasidone in a Clinical Treatment Setting , 2008, Therapeutic drug monitoring.

[566]  Paul Cumming,et al.  Striatal and Extrastriatal D2/D3-Receptor-Binding Properties of Ziprasidone: A Positron Emission Tomography Study With [18F]Fallypride and [11C]Raclopride (D2/D3-Receptor Occupancy of Ziprasidone) , 2008, Journal of clinical psychopharmacology.

[567]  K. Amighi,et al.  Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa. , 2008, International journal of pharmaceutics.

[568]  A. Diefenbacher,et al.  A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation - secondary parameter analyses. , 2008, Pharmacopsychiatry.

[569]  L. Schneider,et al.  Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. , 2008, British journal of clinical pharmacology.

[570]  Paul Gallagher,et al.  STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. , 2008, Age and ageing.

[571]  Howard L McLeod,et al.  Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. , 2008, Pharmacogenomics.

[572]  O. Spigset,et al.  Prescribing Patterns and the Use of Therapeutic Drug Monitoring of Psychotropic Medication in a Psychiatric High-Security Unit , 2008, Therapeutic drug monitoring.

[573]  J. Donovan,et al.  Antipsychotic drugs inhibit the function of breast cancer resistance protein. , 2008, Basic & clinical pharmacology & toxicology.

[574]  E. Spina,et al.  ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active Moiety , 2008, Therapeutic drug monitoring.

[575]  M. Preisig,et al.  Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[576]  E. Franssen,et al.  Toxicokinetics of Dothiepin: 2 Case Reports , 2008, Therapeutic drug monitoring.

[577]  Kazutoshi Ebe,et al.  Plasma amitriptyline level after acute administration, and driving performance in healthy volunteers , 2008, Psychiatry and clinical neurosciences.

[578]  S. Preskorn Practical Application of Therapeutic Drug Monitoring: A Tale of Two Patients , 2008, Journal of psychiatric practice.

[579]  D. Ciraulo,et al.  Relationship between medication adherence and treatment outcomes: the COMBINE study. , 2008, Alcoholism, clinical and experimental research.

[580]  Pierre Marquet,et al.  Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis. , 2008, Clinical chemistry.

[581]  H. Möller,et al.  Striatal D2/D3 Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study , 2008, Pharmacopsychiatry.

[582]  P. Xu,et al.  Pharmacokinetics and tolerability of modafinil tablets in Chinese subjects , 2008, Journal of clinical pharmacy and therapeutics.

[583]  Jingdong Xie,et al.  Pharmacokinetic Interaction Between Efavirenz and Carbamazepine After Multiple‐Dose Administration in Healthy Subjects , 2008, Journal of clinical pharmacology.

[584]  C. Hallert,et al.  Assessment of the Prescription of Antidepressant Drugs in Elderly Nursing Home Patients: A Clinical and Laboratory Follow-Up Investigation , 2008, Journal of clinical psychopharmacology.

[585]  L. Fanton,et al.  Fatal intoxication with milnacipran. , 2008, Journal of forensic and legal medicine.

[586]  Christoph Hiemke,et al.  Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. , 2008, The American journal of psychiatry.

[587]  A. Malhotra,et al.  Clinical and pharmacogenetic studies of iloperidone. , 2008, Personalized medicine.

[588]  M. Foisy,et al.  Induction Effects of Ritonavir: Implications for Drug Interactions , 2008, The Annals of pharmacotherapy.

[589]  P. Riederer,et al.  The Influence of Smoking on the Serum Level of Duloxetine , 2008, Pharmacopsychiatry.

[590]  E. Perucca,et al.  Rufinamide: Clinical pharmacokinetics and concentration–response relationships in patients with epilepsy , 2008, Epilepsia.

[591]  C. Elger,et al.  Population Pharmacokinetics of Lamotrigine with Data from Therapeutic Drug Monitoring in German and Spanish Patients with Epilepsy , 2008, Therapeutic drug monitoring.

[592]  H. Remschmidt,et al.  Large Variability of Aripiprazole and Dehydroaripiprazole Serum Concentrations in Adolescent Patients with Schizophrenia , 2008, Therapeutic drug monitoring.

[593]  B. Bourgeois,et al.  Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies , 2008, Epilepsia.

[594]  B. Pollock,et al.  Anticholinergic Activity of 107 Medications Commonly Used by Older Adults , 2008, Journal of the American Geriatrics Society.

[595]  P. Lillsunde,et al.  Drug testing in oral fluid-evaluation of sample collection devices. , 2008, Journal of analytical toxicology.

[596]  P. Wolf,et al.  Lamotrigine therapeutic thresholds , 2008, Seizure.

[597]  A. Pumariega,et al.  Varenicline-Induced Mixed Mood and Psychotic Episode in a Patient with a Past History of Depression , 2008, CNS Spectrums.

[598]  D. Touw,et al.  Clinical Toxicology of Citalopram After Acute Intoxication With the Sole Drug or in Combination With Other Drugs: Overview of 26 Cases , 2008, Therapeutic drug monitoring.

[599]  J. Markowitz,et al.  Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? , 2008, Journal of clinical psychopharmacology.

[600]  N. Fukui,et al.  Concentration-Response Relationship for Fluvoxamine Using Remission as an Endpoint: A Receiver Operating Characteristics Curve Analysis in Major Depression , 2008, Journal of clinical psychopharmacology.

[601]  Li Ma,et al.  Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. , 2008, Chemico-biological interactions.

[602]  [Expanding therapeutic reference ranges using dose-related reference ranges]. , 2008, Der Nervenarzt.

[603]  J. Hermida,et al.  Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations. , 2008, Clinical biochemistry.

[604]  E. Spina,et al.  Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. , 2008, Pharmacopsychiatry.

[605]  C. Greiner,et al.  Wirkstoffkonzentrationsbestimmungen zur Therapieleitung , 2008, Der Nervenarzt.

[606]  P. Cowen,et al.  Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines , 2008, Journal of psychopharmacology.

[607]  D. Gerostamoulos,et al.  Fatality due to amisulpride toxicity , 2008 .

[608]  Huizhe Wu,et al.  Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. , 2008, Clinical Therapeutics.

[609]  E. Kharasch,et al.  Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) Activity , 2008, Journal of clinical pharmacology.

[610]  N. Brahmi,et al.  Clinical experience with carbamazepine overdose: relationship between serum concentration and neurological severity. , 2008, Journal of clinical psychopharmacology.

[611]  A. Cleton,et al.  Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans , 2008, Drug Metabolism and Disposition.

[612]  R. McGlinchey,et al.  The anticholinergic risk scale and anticholinergic adverse effects in older persons. , 2008, Archives of internal medicine.

[613]  K. Linnet,et al.  A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs , 2008, European Neuropsychopharmacology.

[614]  E. Kharasch,et al.  Role of CYP2B6 in Stereoselective Human Methadone Metabolism , 2008, Anesthesiology.

[615]  R. Kronstrand,et al.  Quantitation of seven low-dosage antipsychotic drugs in human postmortem blood using LC-MS-MS. , 2008, Journal of analytical toxicology.

[616]  P. Gallagher,et al.  Inappropriate prescribing in the older population: need for new criteria. , 2008, Age and ageing.

[617]  Mark A. Smith,et al.  Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. , 2008, Journal of child and adolescent psychopharmacology.

[618]  L. Ekselius,et al.  Identification of primary care patients at risk of nonadherence to antidepressant treatment , 2008, Patient preference and adherence.

[619]  H. Remschmidt,et al.  Large Intraindividual Variability of Olanzapine Serum Concentrations in Adolescent Patients , 2008, Therapeutic drug monitoring.

[620]  H. Arai,et al.  The Relationship Between the Response of Clinical Symptoms and Plasma Olanzapine Concentration, Based on Pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP) , 2008, Therapeutic drug monitoring.

[621]  Z. Jinnan,et al.  Rifabutin autoinduction is caused by involvement of cytochrome P450 and cholinesterase. , 2008, Die Pharmazie.

[622]  A. Gaedigk,et al.  The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype , 2008, Clinical pharmacology and therapeutics.

[623]  J. Hermida,et al.  Clozapine and Norclozapine Concentrations in Serum and Plasma Samples From Schizophrenic Patients , 2008, Therapeutic drug monitoring.

[624]  J. Kirchheiner CYP2D6 Phenotype Prediction From Genotype: Which System Is the Best? , 2008, Clinical pharmacology and therapeutics.

[625]  F. Holsboer,et al.  Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression , 2008, Neuron.

[626]  J. Donovan,et al.  Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein. , 2008, European journal of pharmacology.

[627]  A. Bhatnagar,et al.  The Aldo-Keto Reductase Superfamily and its Role in Drug Metabolism and Detoxification , 2008, Drug metabolism reviews.

[628]  J. Service,et al.  QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone , 2008, Clinical toxicology.

[629]  Matthias J. Müller,et al.  Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[630]  J. Höjer,et al.  Fatal cardiotoxicity induced by venlafaxine overdosage , 2008, Clinical toxicology.

[631]  M. Sargentini-Maier,et al.  Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects , 2008, Drug Metabolism and Disposition.

[632]  B. Ring,et al.  In Vitro and In Vivo Evaluations of Cytochrome P450 1A2 Interactions with Duloxetine , 2008, Clinical pharmacokinetics.

[633]  J. Gorski,et al.  Interaction between midazolam and clarithromycin in the elderly. , 2008, British journal of clinical pharmacology.

[634]  Akihiro Hisaka,et al.  General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information , 2008, Clinical pharmacokinetics.

[635]  D. Gerostamoulos,et al.  Fatality due to amisulpride toxicity: a case report. , 2008, Medicine, science, and the law.

[636]  P. Rolan,et al.  The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. , 2008, British journal of clinical pharmacology.

[637]  H. Neels,et al.  Relevant issues in the monitoring and the toxicology of antidepressants. , 2008, Critical reviews in clinical laboratory sciences.

[638]  S. Kapur,et al.  D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia , 2008, Neuropsychopharmacology.

[639]  Hidehiko Takahashi,et al.  Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia , 2008, Psychopharmacology.

[640]  C. Hiemke Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? , 2008, European Archives of Psychiatry and Clinical Neuroscience.

[641]  H. Sachs,et al.  Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms , 2008, International Journal of Legal Medicine.

[642]  A. Jones Ultra-rapid rate of ethanol elimination from blood in drunken drivers with extremely high blood-alcohol concentrations , 2008, International Journal of Legal Medicine.

[643]  C. Brandt,et al.  „Therapeutic drug monitoring“ in Epileptologie und Psychiatrie , 2008, Der Nervenarzt.

[644]  H. Refsum,et al.  Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele , 2008, European Journal of Clinical Pharmacology.

[645]  Christoph Hiemke,et al.  Clinical utility of drug measurement and pharmacokinetics – therapeutic drug monitoring in psychiatry , 2008, European Journal of Clinical Pharmacology.

[646]  P. Llorca,et al.  Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[647]  M. Reis,et al.  Therapeutic Drug Monitoring of Escitalopram in an Outpatient Setting , 2007, Therapeutic drug monitoring.

[648]  D. Tompson,et al.  Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease. , 2007, Clinical therapeutics.

[649]  C. Halldin,et al.  PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. , 2007, The international journal of neuropsychopharmacology.

[650]  R. Neb,et al.  Serum Concentrations of Pregabalin in Patients With Epilepsy: The Influence of Dose, Age, and Comedication , 2007, Therapeutic drug monitoring.

[651]  G. Sedek,et al.  Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. , 2007, International journal of clinical pharmacology and therapeutics.

[652]  A. Rush,et al.  Maximizing the Adequacy of Medication Treatment in Controlled Trials and Clinical Practice: STAR*D Measurement-Based Care , 2007, Neuropsychopharmacology.

[653]  H. Egger,et al.  Psychopharmacological treatment for very young children: contexts and guidelines. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[654]  L. Endrenyi,et al.  CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine , 2007, Pharmacogenetics and genomics.

[655]  A. Daly,et al.  Factors Affecting Drug Concentrations and QT Interval During Thioridazine Therapy , 2007, Clinical pharmacology and therapeutics.

[656]  R. Turncliff,et al.  Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. , 2007, Journal of studies on alcohol and drugs.

[657]  T. Tracy,et al.  Alterations in drug disposition during pregnancy: implications for drug therapy. , 2007, Expert opinion on drug metabolism & toxicology.

[658]  O. Spigset,et al.  Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. , 2007, The Journal of clinical psychiatry.

[659]  Matthias J. Müller,et al.  Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. , 2007, Journal of psychiatric research.

[660]  R. Croop,et al.  Pharmacokinetics of 6‐hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans , 2007, Biopharmaceutics & drug disposition.

[661]  G. Rongen,et al.  Interaction Study of the Combined Use of Paroxetine and Fosamprenavir-Ritonavir in Healthy Subjects , 2007, Antimicrobial Agents and Chemotherapy.

[662]  Hilde Lunde,et al.  Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole , 2007, European Journal of Clinical Pharmacology.

[663]  H. Stassen,et al.  Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. , 2007, The Journal of clinical psychiatry.

[664]  K. Otani,et al.  Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines , 2007, Journal of clinical pharmacy and therapeutics.

[665]  O. Pelkonen,et al.  Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. , 2007, British journal of clinical pharmacology.

[666]  J. Lindh,et al.  Depot Haloperidol Treatment in Outpatients With Schizophrenia on Monotherapy: Impact of CYP2D6 Polymorphism on Pharmacokinetics and Treatment Outcome , 2007, Therapeutic drug monitoring.

[667]  G. Small,et al.  Pharmacokinetic rationale for the rivastigmine patch , 2007, Neurology.

[668]  B. Winblad,et al.  IDEAL , 2007, Neurology.

[669]  Nick Barber,et al.  Appropriate prescribing in elderly people: how well can it be measured and optimised? , 2007, The Lancet.

[670]  P. Gillman Tricyclic antidepressant pharmacology and therapeutic drug interactions updated , 2007, British journal of pharmacology.

[671]  J. Schwartz The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology , 2007, Clinical pharmacology and therapeutics.

[672]  K. Ohashi,et al.  Effect of the Treatment Period With Erythromycin on Cytochrome P450 3A Activity in Humans , 2007, Journal of clinical pharmacology.

[673]  D. Lancet,et al.  Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication , 2007, Pharmacogenetics and genomics.

[674]  A. Vinks,et al.  Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. , 2007, Clinical therapeutics.

[675]  L. Hirsch,et al.  Effect of Age and Comedication on Levetiracetam Pharmacokinetics and Tolerability , 2007, Epilepsia.

[676]  E. Dunayevich,et al.  All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics: An Integrated Analysis , 2007, Journal of clinical psychopharmacology.

[677]  P. Rolan,et al.  The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. , 2007, British journal of clinical pharmacology.

[678]  Thomas J. Carmody,et al.  Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. , 2007, Psychiatric services.

[679]  H. Druid,et al.  Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels. , 2007, Journal of analytical toxicology.

[680]  S. G. Sakka,et al.  Intoxikation mit einem trizyklischen Antidepressivum , 2007, Der Anaesthesist.

[681]  P. Marquet,et al.  Current role of LC-MS in therapeutic drug monitoring , 2007, Analytical and bioanalytical chemistry.

[682]  Alan A. Wilson,et al.  Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography , 2007, Psychopharmacology.

[683]  C. Eap,et al.  Time course of response to paroxetine: Influence of plasma level , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[684]  J. Leon,et al.  A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. , 2007, Pharmacopsychiatry.

[685]  P. Riederer,et al.  Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence. , 2007, Pharmacopsychiatry.

[686]  B. Volk,et al.  Expression and function of cytochrome p450 in brain drug metabolism. , 2007, Current drug metabolism.

[687]  U. Yasar,et al.  Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients , 2007, Basic & clinical pharmacology & toxicology.

[688]  C. Hiemke,et al.  Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[689]  J. Kane,et al.  Early prediction of antipsychotic nonresponse among patients with schizophrenia. , 2007, The Journal of clinical psychiatry.

[690]  A. Seeringer,et al.  Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. , 2007, Biochimica et biophysica acta.

[691]  M. Gerlach,et al.  Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. , 2007, Pharmacopsychiatry.

[692]  A. Straughn,et al.  Influence of Ethanol and Gender on Methylphenidate Pharmacokinetics and Pharmacodynamics , 2007, Clinical pharmacology and therapeutics.

[693]  A. Serretti,et al.  Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients , 2007, Molecular Psychiatry.

[694]  Jeffrey H Meyer,et al.  Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. , 2007, Journal of psychiatry & neuroscience : JPN.

[695]  J. McCracken,et al.  CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[696]  M. Miura,et al.  Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[697]  A. Saria,et al.  Therapeutic drug monitoring-based clozapine dosing recommendations. , 2007, Therapeutic drug monitoring.

[698]  S. Krishnan,et al.  An Evaluation of the Cytochrome P450 Inhibition Potential of Lisdexamfetamine in Human Liver Microsomes , 2007, Drug Metabolism and Disposition.

[699]  Kaoru Kobayashi,et al.  Identification of Human Cytochrome P450 Isozymes Involved in Diphenhydramine N-Demethylation , 2007, Drug Metabolism and Disposition.

[700]  G. Sedek,et al.  Dose‐Proportional Pharmacokinetics of d‐threo‐Methylphenidate After a Repeated‐Action Release Dosage Form , 2007, Journal of clinical pharmacology.

[701]  S. Benetton,et al.  P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. , 2007, Drug metabolism and pharmacokinetics.

[702]  T. Si,et al.  Pharmacokinetics and Tolerability of Duloxetine following Oral Administration to Healthy Chinese Subjects , 2007, Clinical pharmacokinetics.

[703]  J. de Leon The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. , 2007, Journal of clinical psychopharmacology.

[704]  S. Sakka,et al.  [Intoxication with a tricyclic antidepressant]. , 2007, Der Anaesthesist.

[705]  U. Fuhr,et al.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping , 2007, European Journal of Clinical Pharmacology.

[706]  L. Bertilsson,et al.  Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers , 2007, European Journal of Clinical Pharmacology.

[707]  D. Guay Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. , 2006, The American journal of geriatric pharmacotherapy.

[708]  J. Turgeon,et al.  Inhibitory Effects of Propafenone on the Pharmacokinetics of Caffeine in Humans , 2006, Therapeutic drug monitoring.

[709]  Hilde Lunde,et al.  Pharmacokinetic Variability of Aripiprazole and the Active Metabolite Dehydroaripiprazole in Psychiatric Patients , 2006, Therapeutic drug monitoring.

[710]  M. Stolar,et al.  Multiple‐Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers , 2006, Journal of clinical pharmacology.

[711]  C. Eap,et al.  Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status. , 2006, Journal of clinical psychopharmacology.

[712]  H. Remschmidt,et al.  Serum Levels of Olanzapine and Its N-desmethyl and 2-hydroxymethyl Metabolites in Child and Adolescent Psychiatric Disorders: Effects of Dose, Diagnosis, Age, Sex, Smoking, and Comedication , 2006, Therapeutic drug monitoring.

[713]  B. Birmaher,et al.  Steady-state clinical pharmacokinetics of bupropion extended-release in youths. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[714]  Christoph Hiemke,et al.  Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders. , 2006, Journal of clinical psychopharmacology.

[715]  C. Eap,et al.  ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment , 2006, Clinical pharmacology and therapeutics.

[716]  Yue-Cune Chang,et al.  Optimizing Early Prediction for Antipsychotic Response in Schizophrenia , 2006, Journal of clinical psychopharmacology.

[717]  M. Reimold,et al.  Occupancy of dopamine D1, D2 and serotonin2A receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol , 2006, Psychopharmacology.

[718]  R. Croop,et al.  Pharmacokinetics of a Newly Identified Active Metabolite of Buspirone After Administration of Buspirone Over Its Therapeutic Dose Range , 2006, Journal of clinical pharmacology.

[719]  J. Weide,et al.  Therapeutic Drug Monitoring of Antidepressants and Cytochrome P450 Genotyping in General Practice , 2006, Journal of clinical pharmacology.

[720]  M. Chetty,et al.  Therapeutic Monitoring of Valproate in Psychiatry: How Far Have We Progressed? , 2006, Clinical neuropharmacology.

[721]  B. Zalar,et al.  The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment , 2006, Journal of psychopharmacology.

[722]  Iain M McIntyre,et al.  Therapeutic and toxic concentrations of mirtazapine. , 2006, Journal of analytical toxicology.

[723]  W. Kühn‐Velten,et al.  Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[724]  Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients. , 2006, International journal of clinical pharmacology and therapeutics.

[725]  M. Sandberg,et al.  A first look at duloxetine (Cymbalta) in a postmortem laboratory. , 2006, Journal of analytical toxicology.

[726]  C. Hiemke,et al.  CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine , 2006, Journal of clinical pharmacy and therapeutics.

[727]  L. Ekselius,et al.  Cost of depression: effect of adherence and treatment response , 2006, European Psychiatry.

[728]  Y. Wing,et al.  Phenotype-genotype Relationship and Clinical Effects of Citalopram in Chinese Patients , 2006, Journal of clinical psychopharmacology.

[729]  Soo-Youn Lee,et al.  Pharmacokinetic parameters of bromperidol in Korean subjects , 2006, Human psychopharmacology.

[730]  G. Lombardi,et al.  Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients , 2006, European Journal of Clinical Pharmacology.

[731]  P. Neuvonen,et al.  The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone , 2006, European Journal of Clinical Pharmacology.

[732]  H. Refsum,et al.  Serum concentrations of risperidone and 9‐OH risperidone following intramuscular injection of long‐acting risperidone compared with oral risperidone medication , 2006, Acta psychiatrica Scandinavica.

[733]  M. Owens,et al.  Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities , 2006, Journal of psychopharmacology.

[734]  J. Donovan,et al.  Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein , 2006, Psychopharmacology.

[735]  G. Skopp,et al.  Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes , 2006, European Journal of Clinical Pharmacology.

[736]  H. Maurer,et al.  Toxicokinetics of Drugs of Abuse: Current Knowledge of the Isoenzymes Involved in the Human Metabolism of Tetrahydrocannabinol, Cocaine, Heroin, Morphine, and Codeine , 2006, Therapeutic drug monitoring.

[737]  Kyoung-Ah Kim,et al.  Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects , 2006, Clinical pharmacology and therapeutics.

[738]  A. Guekht,et al.  Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage , 2006, Journal of Clinical Pharmacy and Therapeutics.

[739]  K. Otani,et al.  Rifampicin Markedly Decreases Plasma Concentration and Hypnotic Effect of Brotizolam , 2006, Therapeutic drug monitoring.

[740]  G. Nucci,et al.  Multiple Dose Pharmacokinetics of Paroxetine in Children and Adolescents with Major Depressive Disorder or Obsessive–Compulsive Disorder , 2006, Neuropsychopharmacology.

[741]  J. Drewe,et al.  Hypericum perforatum: Which Constituents may Induce Intestinal MDR1 and CYP3A4 mRNA Expression? , 2006, Planta medica.

[742]  G. Gründer,et al.  Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable , 2006, European Neuropsychopharmacology.

[743]  B. Pollock,et al.  Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. , 2006, British journal of clinical pharmacology.

[744]  N. Moore,et al.  Myocardium distribution of sertindole and its metabolite dehydrosertindole in guinea‐pigs , 2006, Biopharmaceutics & drug disposition.

[745]  B. Birmaher,et al.  Acute Antidepressant Response and Plasma Levels of Bupropion and Metabolites in a Pediatric-Aged Sample: An Exploratory Study , 2006, Therapeutic drug monitoring.

[746]  Time Course of In Vivo 5-HTT Transporter Occupancy by Fluvoxamine , 2006, Journal of clinical psychopharmacology.

[747]  J. Alderman,et al.  Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. , 2006, Journal of child and adolescent psychopharmacology.

[748]  J. Gorski,et al.  The effect of short‐ and long‐term administration of verapamil on the disposition of cytochrome P450 3A and P‐glycoprotein substrates , 2006, Clinical pharmacology and therapeutics.

[749]  P. Neuvonen,et al.  Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide , 2006, Clinical pharmacology and therapeutics.

[750]  S. Kaneko,et al.  Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: A preliminary study , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[751]  E. Perucca British Journal of Clinical Pharmacology Clinically Relevant Drug Interactions with Antiepileptic Drugs , 2022 .

[752]  J. deLeon Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation. , 2006 .

[753]  J. Smoller Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Practical issues related to medication selection. , 2006, CNS spectrums.

[754]  S. Kapur,et al.  A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. , 2006, The American journal of psychiatry.

[755]  G. Kemmler,et al.  Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations , 2006, International clinical psychopharmacology.

[756]  Darin D Dougherty,et al.  PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. , 2006, The American journal of psychiatry.

[757]  Christoph Hiemke,et al.  Appropriateness of Therapeutic Drug Monitoring for Antidepressants in Routine Psychiatric Inpatient Care , 2006, Therapeutic drug monitoring.

[758]  D. Ciraulo,et al.  Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose‐Escalation Trials , 2006, Journal of clinical pharmacology.

[759]  R. Hirschfeld,et al.  Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. , 2006, The American journal of psychiatry.

[760]  C. Hiemke,et al.  Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[761]  Michel Eichelbaum,et al.  Pharmacogenomics and individualized drug therapy. , 2006, Annual review of medicine.

[762]  Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic states , 2006, Nordic journal of psychiatry.

[763]  J. Bobes,et al.  Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence , 2006, European Psychiatry.

[764]  Alexander L. Miller,et al.  Defining and assessing adherence to oral antipsychotics: a review of the literature. , 2005, Schizophrenia bulletin.

[765]  M. Shelton,et al.  Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. , 2006, Clinical pharmacokinetics.

[766]  E. J. Rook,et al.  Population Pharmacokinetics of Heroin and its Major Metabolites , 2006, Clinical pharmacokinetics.

[767]  T. Tomson,et al.  Pharmacokinetic Variability of Newer Antiepileptic Drugs , 2006, Clinical pharmacokinetics.

[768]  C. Eap,et al.  Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance , 2006, Drug safety.

[769]  T. Norman,et al.  Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease , 2006, European Journal of Clinical Pharmacology.

[770]  S. Tanada,et al.  A dose-finding study of duloxetine based on serotonin transporter occupancy , 2006, Psychopharmacology.

[771]  G. Kemmler,et al.  Effects of Age and Sex on Olanzapine Plasma Concentrations , 2005, Journal of clinical psychopharmacology.

[772]  F. Larsen,et al.  The Pharmacokinetics of Escitalopram After Oral and Intravenous Administration of Single and Multiple Doses to Healthy Subjects , 2005, Journal of clinical pharmacology.

[773]  C. Eap,et al.  Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment , 2005, Clinical pharmacology and therapeutics.

[774]  S. Aalto,et al.  Prolonged Central μ-Opioid Receptor Occupancy after Single and Repeated Nalmefene Dosing , 2005, Neuropsychopharmacology.

[775]  W. Katon,et al.  Impact of antidepressant drug adherence on comorbid medication use and resource utilization. , 2005, Archives of internal medicine.

[776]  E. Perucca,et al.  Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. , 2005, Basic & clinical pharmacology & toxicology.

[777]  J. Jefferson,et al.  Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. , 2005, Clinical therapeutics.

[778]  Alexander Lachmann,et al.  The effects of racemic D,L-methadone and L-methadone in substituted patients--a randomized controlled study. , 2005, Drug and alcohol dependence.

[779]  D. Greenblatt,et al.  Clonazepam Pharmacokinetics: Comparison of Subcutaneous Microsphere Injection With Multiple‐Dose Oral Administration , 2005, Journal of clinical pharmacology.

[780]  B. Pollock,et al.  Aging and Clinical Pharmacology: Implications for Antidepressants , 2005, Journal of clinical pharmacology.

[781]  G. Tucker,et al.  Can Saliva Replace Plasma for the Monitoring of Methadone? , 2005, Therapeutic drug monitoring.

[782]  T. Tracy,et al.  CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. , 2005, Biochemical pharmacology.

[783]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[784]  U. Fuhr,et al.  Assessment of CYP1A2 activity in clinical practice: why, how, and when? , 2005, Basic & clinical pharmacology & toxicology.

[785]  J. Finsterer,et al.  Antipsychotic drugs and QT prolongation. , 2005, International clinical psychopharmacology.

[786]  D. Greenblatt,et al.  Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. , 2005, British journal of clinical pharmacology.

[787]  H. Meltzer,et al.  Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. , 2005, The international journal of neuropsychopharmacology.

[788]  W. Fröscher,et al.  Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. , 2005, Epileptic disorders : international epilepsy journal with videotape.

[789]  Matthias J. Müller,et al.  Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. , 2005, Clinical chemistry.

[790]  A. Vulto,et al.  Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed? , 2005, Psychopharmacology.

[791]  K. Otani,et al.  Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. , 2005, British journal of clinical pharmacology.

[792]  A. L. Dal-Fabbro,et al.  Adherence to long term therapies: evidence for action , 2005 .

[793]  D. Berry,et al.  Analysis of Pregabalin at Therapeutic Concentrations in Human Plasma/Serum by Reversed-Phase HPLC , 2005, Therapeutic drug monitoring.

[794]  J. Ahlner,et al.  Inter- and Intraindividual Pharmacokinetic Variations of Mirtazapine and Its N-Demethyl Metabolite in Patients Treated for Major Depressive Disorder: A 6-Month Therapeutic Drug Monitoring Study , 2005, Therapeutic drug monitoring.

[795]  C. Eap,et al.  Increased Clozapine Plasma Concentrations and Side Effects Induced by Smoking Cessation in 2 CYP1A2 Genotyped Patients , 2005, Therapeutic drug monitoring.

[796]  J. Weide,et al.  Metabolic Ratios of Psychotropics as Indication of Cytochrome P450 2D6/2C19 Genotype , 2005, Therapeutic drug monitoring.

[797]  G. Kemmler,et al.  Influence of age and gender on risperidone plasma concentrations , 2005, Journal of psychopharmacology.

[798]  A. Genz,et al.  Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients. , 2005, Pharmacopsychiatry.

[799]  Iain M McIntyre,et al.  Case studies of postmortem quetiapine: therapeutic or toxic concentrations? , 2005, Journal of analytical toxicology.

[800]  L. Martens,et al.  Review: The physiology of saliva and transfer of drugs into saliva. , 2005, Forensic science international.

[801]  L. Brauer,et al.  Inhibition of CYP2D6 Activity by Bupropion , 2005, Journal of clinical psychopharmacology.

[802]  H. Wynne Drug metabolism and ageing , 2005, The journal of the British Menopause Society.

[803]  W. Maier,et al.  Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. , 2005, Pharmacopsychiatry.

[804]  I. Heuser,et al.  Paroxetine serum concentrations in depressed patients and response to treatment. , 2005, Pharmacopsychiatry.

[805]  D. Greenblatt,et al.  Kinetics and Dynamics of Intravenous Adinazolam, N‐Desmethyl Adinazolam, and Alprazolam in Healthy Volunteers , 2005, Journal of clinical pharmacology.

[806]  Qinying Zhao,et al.  Steady‐State Pharmacokinetics of Galantamine Are Not Affected by Addition of Memantine in Healthy Subjects , 2005, Journal of clinical pharmacology.

[807]  A. Heinz,et al.  Is dose escalation of antidepressants a rational strategy after a medium–dose treatment has failed? , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[808]  Tony K L Kiang,et al.  UDP-glucuronosyltransferases and clinical drug-drug interactions. , 2005, Pharmacology & therapeutics.

[809]  C. Hiemke,et al.  Automated Determination of Ziprasidone by HPLC With Column Switching and Spectrophotometric Detection , 2005, Therapeutic drug monitoring.

[810]  R. Obach,et al.  SERTRALINE IS METABOLIZED BY MULTIPLE CYTOCHROME P450 ENZYMES, MONOAMINE OXIDASES, AND GLUCURONYL TRANSFERASES IN HUMAN: AN IN VITRO STUDY , 2005, Drug Metabolism and Disposition.

[811]  A H Thomson,et al.  Cost-Effectiveness of Therapeutic Drug Monitoring: A Systematic Review , 2005, Therapeutic drug monitoring.

[812]  S. Leucht,et al.  Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. , 2005, Clinical chemistry.

[813]  W. Koch,et al.  The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. , 2005, The Journal of clinical psychiatry.

[814]  M. Molimard,et al.  Simplified ultraviolet liquid chromatographic method for determination of sertindole, dehydrosertindole and norsertindole, in human plasma. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[815]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[816]  F. Barale,et al.  Clinical outcome and olanzapine plasma levels in acute schizophrenia , 2005, European Psychiatry.

[817]  G. Simpson,et al.  Plasma clozapine concentration coefficients of variation in a long-term study , 2004, Schizophrenia Research.

[818]  P. Moleman,et al.  A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients , 1996, Psychopharmacology.

[819]  A. Peer,et al.  Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man , 1995, Psychopharmacology.

[820]  H. Wetzel,et al.  Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application , 1994, Psychopharmacology.

[821]  S. Kaplan,et al.  Biopharmaceutical and clinical pharmacokinetic profile of bromazepam , 1976, Journal of Pharmacokinetics and Biopharmaceutics.

[822]  J. Raaflaub On the pharmacokinetics of chlorprothixene in man , 1975, Experientia.

[823]  John-Michael Sauer,et al.  Clinical Pharmacokinetics of Atomoxetine , 2005, Clinical pharmacokinetics.

[824]  S. Preskorn Pharmacokinetics and Therapeutics of Acute Intramuscular Ziprasidone , 2005, Clinical pharmacokinetics.

[825]  M. Linder,et al.  Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice , 2005 .

[826]  H. Möller,et al.  Risperidone plasma levels, clinical response and side–effects , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[827]  K. Kosaki,et al.  A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam , 2004, Brain and Development.

[828]  R. Morris,et al.  Long-Term Follow-Up Using a Higher Target Range for Lamotrigine Monitoring , 2004, Therapeutic drug monitoring.

[829]  K. Nill,et al.  Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol , 2004, The Journal of pharmacy and pharmacology.

[830]  Hans-Georg Buchholz,et al.  High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. , 2004, The international journal of neuropsychopharmacology.

[831]  J. Biederman,et al.  Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[832]  H. Miura Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies , 2004, Seizure.

[833]  G. Anderson Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs , 2004, Neurology.

[834]  D. Greenblatt,et al.  Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate , 2004, Clinical pharmacology and therapeutics.

[835]  B Müller-Oerlinghausen,et al.  The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry , 2004, Pharmacopsychiatry.

[836]  M. Reis,et al.  Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations. , 2004, Journal of affective disorders.

[837]  S. Kaneko,et al.  Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. , 2004, British journal of clinical pharmacology.

[838]  H. Neels,et al.  Therapeutic drug monitoring of old and newer anti-epileptic drugs , 2004, Clinical chemistry and laboratory medicine.

[839]  Henrik Druid,et al.  Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats. , 2004, Journal of analytical toxicology.

[840]  Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. , 2004, British journal of clinical pharmacology.

[841]  H. Hinterhuber,et al.  What the clinician still has to be reminded of. , 2004, Therapeutic drug monitoring.

[842]  K. Linnet,et al.  Quetiapine Serum Concentrations in Psychiatric Patients: The Influence of Comedication , 2004, Therapeutic drug monitoring.

[843]  M. Morrell,et al.  Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy , 2004, Neurology.

[844]  Michael Zschiesche,et al.  Carbamazepine regulates intestinal P‐glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans , 2004, Clinical pharmacology and therapeutics.

[845]  M. Molimard,et al.  Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. , 2004, Toxicology and applied pharmacology.

[846]  P. Weiden,et al.  Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. , 2004, Psychiatric services.

[847]  U. Fuhr,et al.  Time response of cytochrome P450 1A2 activity on cessation of heavy smoking , 2004, Clinical pharmacology and therapeutics.

[848]  C. Hiemke,et al.  Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service. , 2004, Therapeutic drug monitoring.

[849]  C. Eap,et al.  Stereoselective Metabolism of Citalopram in Plasma and Cerebrospinal Fluid of Depressive Patients: Relationship with 5-HIAA in CSF and Clinical Response , 2004, Journal of Clinical Psychopharmacology.

[850]  E. Rüther,et al.  Therapeutic Drug Monitoring of Mirtazapine and Its Metabolite Desmethylmirtazapine by HPLC with Fluorescence Detection , 2004, Therapeutic drug monitoring.

[851]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[852]  S. Kapur,et al.  A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. , 2004, The American journal of psychiatry.

[853]  Sylvain Houle,et al.  Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. , 2004, The American journal of psychiatry.

[854]  J. Kopitz,et al.  Plasma amisulpride levels in schizophrenia or schizoaffective disorder , 2004, European Neuropsychopharmacology.

[855]  Matthias J. Müller,et al.  Therapeutic Monitoring of New Antipsychotic Drugs , 2004, Therapeutic drug monitoring.

[856]  D. Greenblatt,et al.  Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. , 2004, Pharmacogenetics.

[857]  F. Bengtsson Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". , 2004, Therapeutic drug monitoring.

[858]  P. Parzer,et al.  Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. , 2004, Pharmacopsychiatry.

[859]  E. Rüther,et al.  The AMSP Drug Safety Program: Methods and Global Results , 2004, Pharmacopsychiatry.

[860]  E. Rüther,et al.  Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. , 2004, Pharmacopsychiatry.

[861]  C. Hiemke,et al.  Therapeutic Drug Monitoring of the Antidepressant Mirtazapine and Its N-Demethylated Metabolite in Human Serum , 2004, Therapeutic drug monitoring.

[862]  D. Salazar,et al.  Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers , 2004, Journal of clinical pharmacology.

[863]  M. Eichelbaum,et al.  Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine , 2004, Journal of Pharmacology and Experimental Therapeutics.

[864]  U. Breyer‐Pfaff The Metabolic Fate of Amitriptyline, Nortriptyline and Amitriptylinoxide in Man , 2004, Drug metabolism reviews.

[865]  C. Lieber The Discovery of the Microsomal Ethanol Oxidizing System and Its Physiologic and Pathologic Role , 2004, Drug metabolism reviews.

[866]  M. Heathman,et al.  Effect of age on the pharmacokinetics of duloxetine in women. , 2003, British journal of clinical pharmacology.

[867]  P. Demoly,et al.  Antidepressant response and fluvoxamine plasma concentrations: a pilot study , 2003, Pharmacy World and Science.

[868]  C. Hiemke,et al.  The N-Demethylation of the Doxepin Isomers Is Mainly Catalyzed by the Polymorphic CYP2C19 , 2002, Pharmaceutical Research.

[869]  Ralf Regenthal,et al.  Drug Levels: Therapeutic and Toxic Serum/Plasma Concentrations of Common Drugs , 1999, Journal of Clinical Monitoring and Computing.

[870]  S. Kennedy,et al.  Metabolism of Monoamine Oxidase Inhibitors , 1999, Cellular and Molecular Neurobiology.

[871]  F. Bosch,et al.  Torsade de pointes after pipamperone intoxication. , 1998, Pharmacy World and Science.

[872]  D. Morgan,et al.  Clinical pharmacokinetics of chlordiazepoxide in patients with alcoholic hepatitis , 1981, European Journal of Clinical Pharmacology.

[873]  A. Jørgensen Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in viscoleo® , 1980, European Journal of Clinical Pharmacology.

[874]  Trevor R. Norman,et al.  An evaluation of maprotiline intravenous kinetics and comparison of two oral doses , 1980, European Journal of Clinical Pharmacology.

[875]  G. Sedvall,et al.  The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects , 1980, European Journal of Clinical Pharmacology.

[876]  S. Dahl,et al.  Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup , 1977, European Journal of Clinical Pharmacology.

[877]  B. Alexanderson Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: A study in twins , 1973, European Journal of Clinical Pharmacology.

[878]  Y. Nishimura,et al.  Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. , 2004, Journal of pharmacological sciences.

[879]  J. Gerber,et al.  Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. , 2004, Chirality.

[880]  R. Cavallaro,et al.  Citalopram Concentrations and Response in Obsessive-Compulsive Disorder , 2004, CNS drugs.

[881]  G. Gervasini,et al.  Potential Role of Cerebral Cytochrome P450 in Clinical Pharmacokinetics , 2004, Clinical pharmacokinetics.

[882]  F. Hsuan,et al.  Single- vs Multiple-Dose Pharmacokinetics of Clozapine in Psychiatric Patients , 2004, Pharmaceutical Research.

[883]  A. Sluzewska,et al.  Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinical and pharmacokinetic correlates , 2004, European Journal of Clinical Pharmacology.

[884]  K. Midha,et al.  Pharmacokinetics of chlorpromazine and key metabolites , 2004, European Journal of Clinical Pharmacology.

[885]  T. H. Grasela,et al.  Predictive performance of population pharmacokinetic parameters of tianeptine as applied to plasma concentrations from a post-marketing study , 2004, European Journal of Clinical Pharmacology.

[886]  K. Wolff,et al.  Steady-state pharmacokinetics of methadone in opioid addicts , 2004, European Journal of Clinical Pharmacology.

[887]  K. Pittman,et al.  Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses , 2004, European Journal of Clinical Pharmacology.

[888]  R. Grimaldi,et al.  Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects , 2004, European Journal of Clinical Pharmacology.

[889]  P. Bech,et al.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism , 2004, European Journal of Clinical Pharmacology.

[890]  P. Bech,et al.  Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics , 2004, European Journal of Clinical Pharmacology.

[891]  L. Borgström,et al.  Pharmacokinetics of parenteral and oral melperone in man , 2004, European Journal of Clinical Pharmacology.

[892]  N. Klitgaard,et al.  Overdosage of antidepressants: Clinical and pharmacokinetic aspects , 2004, European Journal of Clinical Pharmacology.

[893]  P. Riederer,et al.  Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines , 2004, Psychopharmacology.

[894]  H. Giedke,et al.  Single-dose kinetics of the neuroleptic drug perazine in psychotic patients , 2004, Psychopharmacology.

[895]  U. Bondesson,et al.  Pharmacokinetics of haloperidol in psychotic patients , 2004, Psychopharmacology.

[896]  A. Durand,et al.  Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate , 2004, Psychopharmacology.

[897]  C. Kilts,et al.  Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam , 2004, Psychopharmacology.

[898]  P. Kroboth,et al.  Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration , 2004, Psychopharmacology.

[899]  S. Preskorn,et al.  Brain concentrations of tricyclic antidepressants: Single-dose kinetics and relationship to plasma concentrations in chronically dosed rats , 2004, Psychopharmacology.

[900]  J. Gerlach,et al.  High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin , 2004, Psychopharmacology.

[901]  L. Balant,et al.  Time course of clinical response to venlafaxine: relevance of plasma level and chirality , 2004, European Journal of Clinical Pharmacology.

[902]  E. Kharasch,et al.  Role of P‐glycoprotein in the intestinal absorption and clinical effects of morphine , 2003, Clinical pharmacology and therapeutics.

[903]  M. Bulsara,et al.  Investigation of Target Plasma Concentration-Effect Relationships for Olanzapine in Schizophrenia , 2003, Therapeutic drug monitoring.

[904]  A. Malhotra,et al.  Early prediction of antipsychotic response in schizophrenia. , 2003, The American journal of psychiatry.

[905]  L. Ekselius,et al.  Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners , 2003, International clinical psychopharmacology.

[906]  Jason M. White,et al.  Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. , 2003, Drug and alcohol dependence.

[907]  F. Holsboer,et al.  Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption , 2003, Biological Psychiatry.

[908]  K. Wernecke,et al.  Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics , 2003, Journal of clinical psychopharmacology.

[909]  I. Whyte,et al.  Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. , 2003, British journal of clinical pharmacology.

[910]  J. Spagnoli,et al.  Routine Therapeutic Drug Monitoring in Patients Treated with 10‐360 mg/day Citalopram , 2003, Therapeutic drug monitoring.

[911]  D. Wong,et al.  Mechanism of new antipsychotic medications: occupancy is not just antagonism. , 2003, Archives of general psychiatry.

[912]  L. Kessing,et al.  Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark , 2003, Acta psychiatrica Scandinavica. Supplementum.

[913]  C. Lines,et al.  Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe , 2003, Clinical pharmacology and therapeutics.

[914]  Mats O Karlsson,et al.  Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. , 2003, British journal of clinical pharmacology.

[915]  T. Tomson,et al.  Serum Concentrations and Effects of Gabapentin and Vigabatrin: Observations from a Dose Titration Study , 2003, Therapeutic drug monitoring.

[916]  K. Erlandsson,et al.  Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. , 2003, The American journal of psychiatry.

[917]  M. Brodie,et al.  Topiramate and Lamotrigine Pharmacokinetics during Repetitive Monotherapy and Combination Therapy in Epilepsy Patients , 2003, Epilepsia.

[918]  D. Bates,et al.  Improving safety with information technology. , 2003, The New England journal of medicine.

[919]  L. Bertilsson,et al.  The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes , 2003, Clinical pharmacology and therapeutics.

[920]  N. Kurata,et al.  How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? , 2003, Journal of clinical pharmacy and therapeutics.

[921]  Y. Hishikawa,et al.  Milnacipran plasma levels and antidepressant response in Japanese major depressive patients , 2003, Human psychopharmacology.

[922]  R. Obach,et al.  Ziprasidone Metabolism, Aldehyde Oxidase, and Clinical Implications , 2003, Journal of clinical psychopharmacology.

[923]  T. Tomson,et al.  Therapeutic Drug Monitoring of the Newer Antiepileptic Drugs , 2003, Therapeutic drug monitoring.

[924]  O. Borgå,et al.  Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole , 2003, European Journal of Clinical Pharmacology.

[925]  A. Peer,et al.  Galantamine Population Pharmacokinetics in Patients with Alzheimer's Disease: Modeling and Simulations , 2003, Journal of clinical pharmacology.

[926]  G. Laux,et al.  Therapeutic Drug Monitoring of Tricyclic Antidepressants: How Does it Work under Clinical Conditions? , 2003, Pharmacopsychiatry.

[927]  K. Otani,et al.  Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients , 2003, Psychopharmacology.

[928]  D. Greenblatt,et al.  Short‐Term Exposure to Low‐Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone , 2003, Journal of clinical pharmacology.

[929]  R. Tyndale,et al.  The Role of Cytochrome P450 2C19 Activity in Flunitrazepam Metabolism In Vivo , 2003, Journal of clinical psychopharmacology.

[930]  P. Maurel,et al.  Contribution of human cytochrome P‐450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine , 2003, British journal of pharmacology.

[931]  Liang-Shang Gan,et al.  Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[932]  M. Reis,et al.  Therapeutic Drug Monitoring of Racemic Citalopram: A 5-Year Experience in Sweden, 1992–1997 , 2003, Therapeutic drug monitoring.

[933]  M. Beu,et al.  In vivo measurement of D2 receptor density and affinity for 18F-(3-N-methyl)benperidol in the rat striatum with a PET system for small laboratory animals. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[934]  J. Wilson Survey of Reference Ranges and Clinical Measurements for Psychoactive Drugs in Serum , 2003, Therapeutic drug monitoring.

[935]  F. Bengtsson,et al.  Determination of Serum Reboxetine Enantiomers in Patients on Chronic Medication With Racemic Reboxetine , 2003, Therapeutic drug monitoring.

[936]  Yoshiro Okubo,et al.  High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. , 2003, Archives of general psychiatry.

[937]  S. Reddy,et al.  Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers , 2003, Clinical pharmacology and therapeutics.

[938]  L. S. Steijns,et al.  The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. , 2003, Pharmacogenetics.

[939]  C. Eap,et al.  Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. , 2003, Drug and alcohol dependence.

[940]  David W Bates,et al.  A computer-based intervention for improving the appropriateness of antiepileptic drug level monitoring. , 2003, American journal of clinical pathology.

[941]  D. Greenblatt,et al.  Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[942]  C. Hiemke,et al.  Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[943]  L. Balant,et al.  Therapeutic Drug Monitoring of Olanzapine: The Combined Effect of Age, Gender, Smoking, and Comedication , 2003, Therapeutic drug monitoring.

[944]  U. Bonuccelli,et al.  Clinical Pharmacokinetics of Cabergoline , 2003, Clinical pharmacokinetics.

[945]  B. Bogerts,et al.  Therapeutic drug monitoring of clozapine and relapse--a retrospective study of routine clinical data. , 2003, International journal of clinical pharmacology and therapeutics.

[946]  T. May,et al.  Clinical Pharmacokinetics of Oxcarbazepine , 2003, Clinical pharmacokinetics.

[947]  E. Hellriegel,et al.  Clinical Pharmacokinetic Profile of Modafinil , 2003, Clinical pharmacokinetics.

[948]  P. Baumann,et al.  Clinical outcome after trimipramine in patients with delusional depression - a pilot study. , 2003, Pharmacopsychiatry.

[949]  J. Kane,et al.  The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. , 2003, The Journal of clinical psychiatry.

[950]  E. Mundo,et al.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. , 2003, Drugs.

[951]  M. Balíková,et al.  Plasma levels of dosulepine and heart electric field. , 2003, Physiological research.

[952]  J. de Leon,et al.  Glucuronidation enzymes, genes and psychiatry. , 2003, The international journal of neuropsychopharmacology.

[953]  R. Schall,et al.  Pharmacokinetics of Pipamperone from Three Different Tablet Formulations , 2002, Arzneimittelforschung.

[954]  C. Guillemette,et al.  Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[955]  T. Nakanishi,et al.  Sequential changes in the plasma concentration of risperidone following intentional overdose. , 2002, Clinical neuropharmacology.

[956]  J. Brockmöller,et al.  The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment , 2002, Clinical pharmacology and therapeutics.

[957]  J. Brockmöller,et al.  Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. , 2002, Pharmacogenetics.

[958]  C. Eap,et al.  Enantiomers’ potential in psychopharmacology—a critical analysis with special emphasis on the antidepressant escitalopram , 2002, European Neuropsychopharmacology.

[959]  K. Wesnes,et al.  A Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Acamprosate and Naltrexone , 2002, Neuropsychopharmacology.

[960]  M. Reis,et al.  Therapeutic Drug Monitoring Data on Olanzapine and Its N-Demethyl Metabolite in the Naturalistic Clinical Setting , 2002, Therapeutic drug monitoring.

[961]  K. Otani,et al.  Relationship Between Plasma Concentrations of Trazodone and Its Active Metabolite, m-Chlorophenylpiperazine, and Its Clinical Effect in Depressed Patients , 2002, Therapeutic drug monitoring.

[962]  M. Reis,et al.  Therapeutic Drug Monitoring of Racemic Venlafaxine and Its Main Metabolites in an Everyday Clinical Setting , 2002, Therapeutic drug monitoring.

[963]  J. Ahlner,et al.  Serum Levels of Citalopram and Its Main Metabolites in Adolescent Patients Treated in a Naturalistic Clinical Setting , 2002, Journal of clinical psychopharmacology.

[964]  Josemir W Sander,et al.  Sulthiame in adults with refractory epilepsy and learning disability: an open trial , 2002, Epilepsy Research.

[965]  I. Meineke,et al.  Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach , 2002, European Journal of Clinical Pharmacology.

[966]  G. Koren,et al.  How High Can We Go With Phenytoin? , 2002, Therapeutic drug monitoring.

[967]  P. Danos,et al.  Serum Concentration of Chlormethiazole and Therapeutic Effect in Acute Alcohol Withdrawal Syndrome: An Open Clinical Trial , 2002, Therapeutic drug monitoring.

[968]  T. May,et al.  Serum Concentrations of Topiramate in Patients With Epilepsy: Influence of Dose, Age, and Comedication , 2002, Therapeutic drug monitoring.

[969]  M. Preisig,et al.  Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. , 2002, International clinical psychopharmacology.

[970]  T. Marandi,et al.  Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype , 2002, Psychopharmacology.

[971]  D. Yim,et al.  Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. , 2002, British journal of clinical pharmacology.

[972]  Qinying Zhao,et al.  Pharmacokinetics and Safety of Galantamine in Subjects with Hepatic Impairment and Healthy Volunteers , 2002, Journal of clinical pharmacology.

[973]  S. Arora,et al.  Steady‐State Pharmacokinetics and Tolerability of Modafinil Administered Alone or in Combination with Dextroamphetamine in Healthy Volunteers , 2002, Journal of clinical pharmacology.

[974]  C. Martini,et al.  Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients Influence of patient-related variables , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[975]  I. Lamster,et al.  The diagnostic applications of saliva--a review. , 2002, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[976]  A. Laudet,et al.  Adherence to medication regimens and participation in dual-focus self-help groups. , 2002, Psychiatric services.

[977]  Jan Scott,et al.  Treatment non‐adherence in affective disorders , 2002, Acta psychiatrica Scandinavica.

[978]  U. Fuhr,et al.  Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. , 2002, Pharmacology & toxicology.

[979]  G. Ferron,et al.  Multiple‐Dose, Linear, Dose‐Proportional Pharmacokinetics of Retigabine in Healthy Volunteers , 2002, Journal of clinical pharmacology.

[980]  P. Rosenzweig,et al.  A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers , 2002, Human psychopharmacology.

[981]  D. Deleu,et al.  Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease , 2002, Clinical pharmacokinetics.

[982]  J. Läuter,et al.  Comprehensive Survey of the Relationship Between Serum Concentration and Therapeutic Effect of Amitriptyline in Depression , 2002, Clinical pharmacokinetics.

[983]  J. Potter,et al.  Pharmacogenetic screening and therapeutic drugs. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[984]  J. Markowitz,et al.  Clinical Pharmacokinetics of Sertraline , 2002, Clinical pharmacokinetics.

[985]  P. Joyce,et al.  A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression , 2002, The Pharmacogenomics Journal.

[986]  G. Small,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors , 2002, Clinical pharmacokinetics.

[987]  T. Buclin,et al.  Interindividual Variability of the Clinical Pharmacokinetics of Methadone , 2002, Clinical pharmacokinetics.

[988]  S. Tett,et al.  Population Pharmacokinetics of Lamotrigine , 2001, Therapeutic drug monitoring.

[989]  J. Ahlner,et al.  Enantioselective Analysis of Citalopram and Metabolites in Adolescents , 2001, Therapeutic drug monitoring.

[990]  P. Tigel,et al.  Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults , 2001, European Neuropsychopharmacology.

[991]  J. Urquhart,et al.  Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors , 2001, British Journal of Psychiatry.

[992]  C. Hiemke,et al.  Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[993]  O. Olesen,et al.  Contributions of Five Human Cytochrome P450 Isoforms to the N‐demethylation of Clozapine In Vitro at Low and High Concentrations , 2001, Journal of clinical pharmacology.

[994]  E. Ezan,et al.  Erythromycin increases plasma concentrations of α‐dihydroergocryptine in humans , 2001, Clinical pharmacology and therapeutics.

[995]  J S Harmatz,et al.  Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[996]  R. Radtke Pharmacokinetics of Levetiracetam , 2001, Epilepsia.

[997]  S. Leucht,et al.  Doxepin Plasma Concentrations: Is There Really a Therapeutic Range? , 2001, Journal of clinical psychopharmacology.

[998]  C. Naranjo,et al.  Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram , 2001, European Neuropsychopharmacology.

[999]  N. Delva,et al.  Preventing lithium intoxication. Guide for physicians. , 2001, Canadian family physician Medecin de famille canadien.

[1000]  Zhaoqian Liu,et al.  Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.

[1001]  P. Genton,et al.  Tiagabine in Clinical Practice , 2001, Epilepsia.

[1002]  N. Gupta,et al.  Guidelines for lithium monitoring: are they ideal? , 2001, Acta psychiatrica Scandinavica.

[1003]  K. Dietz,et al.  Therapeutic Drug Monitoring of Clozapine in Relapse Prevention: A Five-Year Prospective Study , 2001, Journal of clinical psychopharmacology.

[1004]  E. D. Glover,et al.  Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. , 2001, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[1005]  K. Vasudev,et al.  Pharmacokinetics of valproic acid in patients with bipolar disorder , 2001, Journal of psychopharmacology.

[1006]  K. Brøsen,et al.  Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6 , 2001, European Journal of Clinical Pharmacology.

[1007]  F. Oesch,et al.  Differential Effects of Fluvoxamine and Other Antidepressants on the Biotransformation of Melatonin , 2001, Journal of clinical psychopharmacology.

[1008]  B. Lerer,et al.  Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia , 2001, Molecular Psychiatry.

[1009]  C. Peterson,et al.  Bioanalysis of Racemic Reboxetine and Its Desethylated Metabolite in a Therapeutic Drug Monitoring Setting Using Solid Phase Extraction and HPLC , 2001, Therapeutic drug monitoring.

[1010]  M. Mauri,et al.  Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels , 2001, European Psychiatry.

[1011]  H. Zhou,et al.  Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. , 2001, Acta pharmacologica Sinica.

[1012]  N. Delva,et al.  Preventing lithium intoxication , 2001 .

[1013]  P. Perry Therapeutic drug monitoring of antipsychotics. , 2001, Psychopharmacology bulletin.

[1014]  M. Müller,et al.  Serum Levels of Sulpiride Enantiomers after Oral Treatment with Racemic Sulpiride in Psychiatric Patients: a Pilot Study1 , 2001, Pharmacopsychiatry.

[1015]  P. Pentikäinen,et al.  Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man , 2001, European Journal of Clinical Pharmacology.

[1016]  O. Olesen,et al.  Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. , 2008, British journal of clinical pharmacology.

[1017]  E. Wyska,et al.  Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression , 2001, Psychopharmacology.

[1018]  J. Spagnoli,et al.  Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. , 2000, Drug and alcohol dependence.

[1019]  R. Weaver,et al.  Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[1020]  D. Stanski,et al.  Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. , 2000, Clinical therapeutics.

[1021]  S. Yamaguchi,et al.  CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. , 2000, Life sciences.

[1022]  B. Lerer,et al.  Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility , 2000, Psychopharmacology.

[1023]  A. Somogyi,et al.  Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. , 2000, British journal of clinical pharmacology.

[1024]  B. Burchell,et al.  The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[1025]  O. Spigset,et al.  Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis , 2000, European Journal of Clinical Pharmacology.

[1026]  M. Romkes,et al.  In vivo modulation of CYP enzymes by quinidine and rifampin , 2000, Clinical pharmacology and therapeutics.

[1027]  C. Kaye,et al.  Clinical Pharmacokinetics of Ropinirole , 2000, Clinical pharmacokinetics.

[1028]  D. Greenblatt,et al.  Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[1029]  Stewart B. Leavitt,et al.  When "enough" is not enough: new perspectives on optimal methadone maintenance dose. , 2000, The Mount Sinai journal of medicine, New York.

[1030]  J. Brockmöller,et al.  Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro , 2000, Psychopharmacology.

[1031]  R. Freese,et al.  Forensic psychiatric assessment and treatment in Germany. Legal framework, recent developments, and current practice. , 2000, International journal of law and psychiatry.

[1032]  J. A. Carrillo,et al.  Clinically Significant Pharmacokinetic Interactions Between Dietary Caffeine and Medications , 2000, Clinical pharmacokinetics.

[1033]  B L Ehrenberg,et al.  Kinetics and dynamics of lorazepam during and after continuous intravenous infusion , 2000, Critical care medicine.

[1034]  T. Glauser,et al.  Controversies in Blood‐level Monitoring: Reexamining Its Role in the Treatment of Epilepsy , 2000, Epilepsia.

[1035]  P. Robertson,et al.  In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[1036]  C J Timmer,et al.  Clinical Pharmacokinetics of Mirtazapine , 2000, Clinical pharmacokinetics.

[1037]  S. Gacinovic,et al.  Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study , 2000, Psychopharmacology.

[1038]  M. Reis,et al.  Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients , 2000, Acta psychiatrica Scandinavica.

[1039]  J. Eagles,et al.  Lithium monitoring before and after the distribution of clinical practice guidelines , 2000, Acta psychiatrica Scandinavica.

[1040]  G. Houin,et al.  Pharmacokinetics of Single‐Dose Reboxetine in Volunteers with Renal Insufficiency , 2000, Journal of clinical pharmacology.

[1041]  K. Vasudev,et al.  Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder , 2000, Psychopharmacology.

[1042]  C. Eap,et al.  Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. , 2000, Therapeutic drug monitoring.

[1043]  T. Someya,et al.  Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. , 2000, Journal of Clinical Psychopharmacology.

[1044]  B H Mulsant,et al.  Pharmacologic profile of perphenazine's metabolites. , 2000, Journal of clinical psychopharmacology.

[1045]  K. Brøsen,et al.  Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? , 2000, Therapeutic drug monitoring.

[1046]  P. Haffmans,et al.  Venlafaxine serum levels and CYP2D6 genotype. , 2000, Therapeutic drug monitoring.

[1047]  F. Holsboer,et al.  Penetration of Amitriptyline, but Not of Fluoxetine, into Brain is Enhanced in Mice with Blood-Brain Barrier Deficiency Due to Mdr1a P-Glycoprotein Gene Disruption , 2000, Neuropsychopharmacology.

[1048]  C. Hiemke,et al.  Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[1049]  K. Shulman,et al.  Differential Pharmacokinetics of Lithium in Elderly Patients , 2000, Drugs & aging.

[1050]  J. Castell,et al.  In vitro identification of the cytochrome P450 isoform responsible for the metabolism of a-dihydroergocryptine , 2000 .

[1051]  D. Tweedie,et al.  Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. , 2000, British journal of clinical pharmacology.

[1052]  P. Saidón,et al.  [Pharmacokinetic variability of oxcarbazepine in epileptic patients]. , 2000, Medicina.

[1053]  C. Hiemke,et al.  Pharmacokinetics of selective serotonin reuptake inhibitors. , 2000, Pharmacology & therapeutics.

[1054]  E. Perucca,et al.  Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia , 2000, Psychopharmacology.

[1055]  S. Kapur,et al.  Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels , 2000, Psychopharmacology.

[1056]  M. Smyth,et al.  Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. , 2000, The Analyst.

[1057]  T. Thomsen,et al.  The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. , 1999, Pharmacogenetics.

[1058]  L. Wienkers,et al.  Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[1059]  S. Marder,et al.  Pharmacokinetics and tissue distribution of olanzapine in rats , 1999, Biopharmaceutics & drug disposition.

[1060]  O. Dulac,et al.  Stiripentol: Efficacy and Tolerability in Children with Epilepsy , 1999, Epilepsia.

[1061]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[1062]  J. Fleishaker,et al.  Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans , 1999, Clinical pharmacology and therapeutics.

[1063]  F. Bengtsson,et al.  Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. , 1999, Therapeutic drug monitoring.

[1064]  L. Bertilsson,et al.  Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. , 1999, Journal of clinical psychopharmacology.

[1065]  C. Beasley,et al.  Olanzapine. Pharmacokinetic and pharmacodynamic profile. , 1999, Clinical pharmacokinetics.

[1066]  P Jaillon,et al.  Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[1067]  D. Flockhart,et al.  Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[1068]  S. Preskorn,et al.  Therapeutic Drug Monitoring of Antidepressants , 1999 .

[1069]  D. Greenblatt,et al.  Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. , 1999, British journal of clinical pharmacology.

[1070]  K. Otani,et al.  Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients , 1999, Psychopharmacology.

[1071]  Suneel K. Gupta,et al.  Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. , 1999, British journal of clinical pharmacology.

[1072]  D. Kupfer,et al.  Therapeutic drug monitoring of mood stabilizers in Medicaid patients with bipolar disorder. , 1999, The American journal of psychiatry.

[1073]  Karthik Venkatakrishnan,et al.  Nortriptyline E‐10‐Hydroxylation in Vitro Is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low Affinity): Implications for Interactions with Enzyme‐Inducing Drugs , 1999, Journal of clinical pharmacology.

[1074]  E. Kharasch,et al.  Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[1075]  J. Röschke,et al.  Oxybutynin enhances the metabolism of clomipramine and dextrorphan possibly by induction of a cytochrome P450 isoenzyme. , 1999, Journal of clinical psychopharmacology.

[1076]  P. O'Connor,et al.  Plasma concentrations of buprenorphine 24 to 72 hours after dosing. , 1999, Drug and alcohol dependence.

[1077]  T. Self,et al.  Isoniazid drug and food interactions. , 1999, The American journal of the medical sciences.

[1078]  D. Greenblatt,et al.  O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants , 1999, Neuropsychopharmacology.

[1079]  D. Brocks Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. , 1999, Journal of Pharmacy & Pharmaceutical Sciences.

[1080]  I. Mahmood,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug , 1999, Clinical pharmacokinetics.

[1081]  David Back,et al.  Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection , 1999, Clinical pharmacokinetics.

[1082]  J. A. Carrillo,et al.  Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2‐receptor antagonists , 1999, Clinical pharmacology and therapeutics.

[1083]  J. Larsen,et al.  The effect of tolcapone on the pharmacokinetics of benserazide , 1999, European journal of neurology.

[1084]  C. DeVane,et al.  Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. , 1999, The international journal of neuropsychopharmacology.

[1085]  M. Alda Pharmacogenetics of lithium response in bipolar disorder. , 1999, Journal of psychiatry & neuroscience : JPN.

[1086]  Y. Wong,et al.  Open‐Label, Single‐Dose Pharmacokinetic Study of Modafinil Tablets: Influence of Age and Gender in Normal Subjects , 1999, Journal of clinical pharmacology.

[1087]  W. Trager,et al.  In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[1088]  M. Piercey,et al.  Pramipexole — a new dopamine agonist for the treatment of Parkinson's disease , 1999, Journal of the Neurological Sciences.

[1089]  L. Balant,et al.  Clomipramine concentration as a predictor of delayed response: a naturalistic study , 1999, European Journal of Clinical Pharmacology.

[1090]  D. Flockhart,et al.  Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6) , 1999, Clinical pharmacology and therapeutics.

[1091]  Y. Wong,et al.  A Double‐Blind, Placebo‐Controlled, Ascending‐Dose Evaluation of the Pharmacokinetics and Tolerability of Modafinil Tablets in Healthy Male Volunteers , 1999, Journal of clinical pharmacology.

[1092]  E. Gouws,et al.  The use of a side effect as a qualitative indicator of plasma chlorpromazine levels , 1999, European Neuropsychopharmacology.

[1093]  G. Baker,et al.  Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[1094]  K. Iwasaki,et al.  Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[1095]  A. Somogyi,et al.  Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[1096]  K. Antonin,et al.  [Pharmacokinetics and relative bioavailability of opipramol in the new INSIDON--sustained release preparation]. , 1998, Fortschritte der Neurologie-Psychiatrie.

[1097]  G. Granneman,et al.  Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies. , 1998, Journal of pharmaceutical sciences.

[1098]  R. Morris,et al.  Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. , 1998, British journal of clinical pharmacology.

[1099]  T. Mimaki,et al.  Clinical pharmacology and therapeutic drug monitoring of zonisamide. , 1998, Therapeutic drug monitoring.

[1100]  J. Gerven,et al.  Pharmacodynamics and Pharmacokinetics of a Single Oral Dose of Nitrazepam in Healthy Volunteers: An Interethnic Comparative Study between Japanese and European Volunteers , 1998, Journal of clinical pharmacology.

[1101]  M. Bertolotti,et al.  Serum time course of naltrexone and 6 beta-naltrexol levels during long-term treatment in drug addicts. , 1998, Drug and alcohol dependence.

[1102]  G. Houin,et al.  Clinical Pharmacokinetics of Acamprosate , 1998, Clinical pharmacokinetics.

[1103]  L. Friedhoff,et al.  Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. , 1998, British journal of clinical pharmacology.

[1104]  D. Greenblatt,et al.  Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo , 1998, Clinical pharmacology and therapeutics.

[1105]  N. Wood,et al.  Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects , 1998, Psychopharmacology.

[1106]  E. Tanaka,et al.  Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines, and tricyclic and tetracyclic antidepressants – an update , 1998, Journal of clinical pharmacy and therapeutics.

[1107]  C. Bowden,et al.  Bupropion slow-release response in depression: diagnosis and biochemistry , 1998, Biological Psychiatry.

[1108]  S. Marder,et al.  Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat , 1998, Psychopharmacology.

[1109]  M. D. Faiman,et al.  Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. , 1998, Alcoholism, clinical and experimental research.

[1110]  A. Puech,et al.  Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose‐ranging study vs. haloperidol , 1998 .

[1111]  B. Testa,et al.  Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. , 1998, Biochemical pharmacology.

[1112]  P. Heizmann,et al.  Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy , 1998, European Journal of Clinical Pharmacology.

[1113]  C. Hiemke,et al.  Automated determination of clomipramine and its major metabolites in human and rat serum by high-performance liquid chromatography with on-line column-switching. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[1114]  S. Rotzinger,et al.  Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[1115]  M. Contin,et al.  Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled is release in parkinsonian patients , 1998, European Journal of Clinical Pharmacology.

[1116]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[1117]  D. Flockhart,et al.  Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. , 1998, The Journal of pharmacology and experimental therapeutics.

[1118]  P. Keck,et al.  Standards of laboratory practice: antidepressant drug monitoring , 1998 .

[1119]  M. Lappenberg-Pelzer Identification and determination of opipramol metabolites in plasma and urine. , 1998, Journal of analytical toxicology.

[1120]  R. Polinsky,et al.  Dose‐dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease , 1998, Acta neurologica Scandinavica.

[1121]  E. Cone,et al.  Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. , 1998, Addiction.

[1122]  C. Wurthmann,et al.  The Relationship Between Serum Concentration and Therapeutic Effect of Haloperidol in Patients with Acute Schizophrenia , 1998, Clinical pharmacokinetics.

[1123]  D. Greenblatt,et al.  Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir , 1998, Journal of clinical pharmacology.

[1124]  K. Otani,et al.  Single oral dose kinetics of zotepine and its relationship to prolactin response and side effects. , 1998, Therapeutic drug monitoring.

[1125]  F. Macciardi,et al.  Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. , 1998, Therapeutic drug monitoring.

[1126]  K. Wilner,et al.  The Effect of Timing of a Standard Meal on the Pharmacokinetics and Pharmacodynamics of the Novel Atypical Antipsychotic Agent Ziprasidone , 1998, Pharmacotherapy.

[1127]  D. G. Walters,et al.  Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[1128]  A. Puech,et al.  Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. , 1998, Acta Psychiatrica Scandinavica.

[1129]  G. Bertschy,et al.  High interindividual variability of methadone enantiomer blood levels to dose ratios. , 1998, Archives of general psychiatry.

[1130]  M. Contin,et al.  Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients. , 1998, European journal of clinical pharmacology.

[1131]  P. Keck,et al.  Standards of laboratory practice: antidepressant drug monitoring. National Academy of Clinical Biochemistry. , 1998, Clinical chemistry.

[1132]  Jürgen Gallinat,et al.  The serotonin syndrome scale: first results on validity , 1998, European Archives of Psychiatry and Clinical Neuroscience.

[1133]  A. Mallet,et al.  Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. , 2003, British journal of clinical pharmacology.

[1134]  M. Danhof,et al.  A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. , 2003, British journal of clinical pharmacology.

[1135]  A. Nomeir,et al.  Single and multiple dose pharmacokinetics of felbamate in the elderly. , 2003, British journal of clinical pharmacology.

[1136]  K. Kudo,et al.  Plasma concentrations of antipsychotic drugs in psychiatric inpatients. , 1997, Nihon hoigaku zasshi = The Japanese journal of legal medicine.

[1137]  C. Beasley,et al.  Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. , 1997, Journal of clinical psychopharmacology.

[1138]  L. Wienkers,et al.  Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[1139]  R. Arteaga,et al.  Vigabatrin serum concentration to dosage ratio: influence of age and associated antiepileptic drugs. , 1997, Therapeutic drug monitoring.

[1140]  A. Somogyi,et al.  Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. , 1997, Journal of pain and symptom management.

[1141]  S. Tsuchida,et al.  Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine , 1997, Psychopharmacology.

[1142]  R. Bergstrom,et al.  The effect of sertraline on the pharmacokinetics of desipramine and imipramine , 1997, Clinical pharmacology and therapeutics.

[1143]  C. Hiemke,et al.  Automated determination of clozapine and major metabolites in serum and urine. , 1997, Therapeutic drug monitoring.

[1144]  U. Bergman,et al.  The utilization of antidemessants — a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992‐1994 , 1997, Acta psychiatrica Scandinavica.

[1145]  M. Murray,et al.  Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. , 1997, The Journal of pharmacology and experimental therapeutics.

[1146]  K. Otani,et al.  Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. , 1997, Therapeutic drug monitoring.

[1147]  O. Olesen,et al.  Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[1148]  C. Wright,et al.  Steady‐State Pharmacokinetic Properties of Pramipexole in Healthy Volunteers , 1997, Journal of clinical pharmacology.

[1149]  S. Hirsch,et al.  Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. , 1997, Archives of general psychiatry.

[1150]  I. Heuser,et al.  Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients , 1997, Psychopharmacology.

[1151]  W. Potter,et al.  The Role of Metabolites of Antidepressants in the Treatment of Depression , 1997, CNS drugs.

[1152]  R. Causon Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[1153]  H. Kroemer,et al.  Use of Probe Drugs as Predictors of Drug Metabolism in Humans , 1997, Journal of clinical pharmacology.

[1154]  G. Granneman,et al.  Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function , 1997, European Journal of Clinical Pharmacology.

[1155]  G. Grollier,et al.  Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. , 1997, Chirality.

[1156]  L. Tremaine,et al.  Pharmacokinetics of Sertraline and its N-Demethyl Metabolite in Elderly and Young Male and Female Volunteers , 1997, Clinical pharmacokinetics.

[1157]  U. Gundert-Remy,et al.  Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? , 1997, European Journal of Clinical Pharmacology.

[1158]  R. Frye,et al.  The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. , 2003, British journal of clinical pharmacology.

[1159]  P. Baumann Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors , 1996, Clinical pharmacokinetics.

[1160]  C. Eap,et al.  Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. , 1996, Journal of chromatography. B, Biomedical applications.

[1161]  T. Aoyama,et al.  Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[1162]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .

[1163]  T. Kamataki,et al.  CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. , 1996, Pharmacogenetics (London).

[1164]  H. Zhou,et al.  The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. , 1996, British journal of clinical pharmacology.

[1165]  M. Strolin Benedetti,et al.  Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. , 1996, Biopharmaceutics & drug disposition.

[1166]  K. Otani,et al.  No interaction between desipramine and bromperidol , 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[1167]  E. Perucca,et al.  Clinically Significant Pharmacokinetic Drug Interactions with Carbamazepine , 1996, Clinical pharmacokinetics.

[1168]  A. Schmoldt,et al.  One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites. , 1996, Journal of analytical toxicology.

[1169]  G. Wilkinson,et al.  Disposition of diazepam in young and elderly subjects after acute and chronic dosing. , 1996, British journal of clinical pharmacology.

[1170]  C. Hiemke,et al.  The role of cytochrome P450 2D6 in the metabolism of moclobemide , 1996, European Neuropsychopharmacology.

[1171]  K. Chiba,et al.  Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. , 1996, The Journal of pharmacology and experimental therapeutics.

[1172]  Rinne Uk,et al.  Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. , 1996 .

[1173]  M. Contin,et al.  Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease , 1996, Clinical pharmacokinetics.

[1174]  K. Olkkola,et al.  Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system. , 1996, Pharmacology & toxicology.

[1175]  P. Beaune,et al.  Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. , 1996, Pharmacogenetics (London).

[1176]  L. Bertilsson,et al.  The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol , 1996, Clinical pharmacology and therapeutics.

[1177]  P. Neuvonen,et al.  Concentrations and Effects of Oral Midazolam are Greatly Reduced in Patients Treated with Carbamazepine or Phenytoin , 1996, Epilepsia.

[1178]  C. Eap,et al.  Plasma levels of the enantiomers of thioridazine, thioridazine 2‐sulfoxide, thioridazine 2‐sulfone, and thioridazine 5‐sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin , 1996, Clinical pharmacology and therapeutics.

[1179]  C. Harden,et al.  Felbamate Levels in Patients with Epilepsy , 1996, Epilepsia.

[1180]  H. Möller,et al.  Pharmacokinetics of chlorprothixene after single intravenous and oral administration of three galenic preparations. , 1996, Arzneimittel-Forschung.

[1181]  M. Gastpar,et al.  Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone , 1996, Addiction biology.

[1182]  A. Gill,et al.  Steady-State Plasma Concentrations of Midazolam in Critically Ill Infants and Children , 1996, The Annals of pharmacotherapy.

[1183]  J. McEvoy,et al.  Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. , 1996, The American journal of psychiatry.

[1184]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. , 1996, Dementia.

[1185]  H. Ruottinen,et al.  Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. , 1996, Clinical neuropharmacology.

[1186]  N. Scherbaum,et al.  Replacement of (R)-methadone by a double dose of (R, S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics , 1996, European Journal of Clinical Pharmacology.

[1187]  G. Sedek,et al.  Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects , 1996, European Journal of Clinical Pharmacology.

[1188]  S. Loft,et al.  Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine , 1996, European Journal of Clinical Pharmacology.

[1189]  H. Möller,et al.  Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. , 1995, International journal of clinical pharmacology and therapeutics.

[1190]  R. Farinotti,et al.  Clinical Pharmacokinetics of Zopiclone , 1995, Clinical pharmacokinetics.

[1191]  R. Baldessarini,et al.  Distribution of Fluphenazine and Its Metabolites in Brain Regions and Other Tissues of the Rat , 1995, Neuropsychopharmacology.

[1192]  B. Salomon,et al.  Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. , 1995, European journal of pharmacology.

[1193]  P. Glue,et al.  Effects of felbamate on the pharmacokinetics of phenobarbital , 1995, Clinical pharmacology and therapeutics.

[1194]  B. Pollock,et al.  Pharmacokinetics of Single‐ and Multiple‐Dose Bupropion in Elderly Patients with Depression , 1995, Journal of clinical pharmacology.

[1195]  K. Otani,et al.  Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. , 1995, International clinical psychopharmacology.

[1196]  P. Salvà,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem , 1995, Clinical pharmacokinetics.

[1197]  C. Halldin,et al.  Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man , 1995, International clinical psychopharmacology.

[1198]  E. Chi,et al.  Safety, Tolerability, and Effect of Food on the Pharmacokinetics of Iloperidone (HP 873), a Potential Atypical Antipsychotic , 1995, Journal of clinical pharmacology.

[1199]  K. Jellinger,et al.  Therapeutic brain concentration of the NMDA receptor antagonist amantadine , 1995, Neuropharmacology.

[1200]  K. Brøsen,et al.  Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study * , 1995, Clinical pharmacology and therapeutics.

[1201]  K. Brøsen,et al.  Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. , 1995, British journal of clinical pharmacology.

[1202]  T. Davis,et al.  The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. , 1995, British journal of clinical pharmacology.

[1203]  L. Dubé,et al.  Effect of Zileuton on Theophylline Pharmacokinetics , 1995, Clinical pharmacokinetics.

[1204]  O. Olesen,et al.  Search for a Therapeutic Range for Serum Zuclopenthixol Concentrations in Schizophrenic Patients , 1994, Therapeutic drug monitoring.

[1205]  A. Mallet,et al.  Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method. , 1994, British journal of clinical pharmacology.

[1206]  M. Delaforge,et al.  High affinity of ergopeptides for cytochromes P450 3A. Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine. , 1994, European Journal of Biochemistry.

[1207]  A. Szegedi,et al.  Automated Determination of Paroxetine and Its Main Metabolite by Column Switching and On‐Line High‐Performance Liquid Chromatography , 1994, Therapeutic drug monitoring.

[1208]  Stephan Arndt,et al.  Tricyclic Antidepressant Concentrations in Plasma: An Estimate of Their Sensitivity and Specificity as a Predictor of Response , 1994, Journal of clinical psychopharmacology.

[1209]  A. Bond,et al.  Systemic absorption and abuse liability of snorted flunitrazepam. , 1994, Addiction.

[1210]  McLean Mj Clinical pharmacokinetics of gabapentin. , 1994 .

[1211]  D. Kroetz,et al.  Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. , 1994, Biochemical pharmacology.

[1212]  R Jouvent,et al.  Nonparametric Estimation of Population Characteristics of the Kinetics of Lithium from Observational and Experimental Data: Individualization of Chronic Dosing Regimen Using a New Bayesian Approach , 1994, Therapeutic drug monitoring.

[1213]  M. McLean Clinical pharmacokinetics of gabapentin , 1994, Neurology.

[1214]  T. May,et al.  Pharmacokinetics of Sulthiame in Epileptic Patients , 1994, Therapeutic drug monitoring.

[1215]  K. Otani,et al.  Adverse Effects of Zotepine and Their Relationship To Serum Concentrations of the Drug and Prolactin , 1994, Therapeutic drug monitoring.

[1216]  M. E. Ward,et al.  Clinical Pharmacokinetics of Lithium , 1994, Journal of clinical pharmacology.

[1217]  A. Altamura,et al.  Clinical Pharmacokinetics of Fluoxetine , 1994, Clinical pharmacokinetics.

[1218]  R. Gupta,et al.  Therapeutic monitoring of sertraline. , 1994, Clinical chemistry.

[1219]  L. Bertilsson,et al.  The Use of Therapeutic Drug Monitoring Data to Document Kinetic Drug Interactions: An Example with Amitriptyline and Nortriptyline , 1994, Therapeutic drug monitoring.

[1220]  N. Buckley,et al.  Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants , 1994, The Lancet.

[1221]  P. Baumann,et al.  Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry. , 1994, Journal of chromatography.

[1222]  M. Mark,et al.  Pharmacokinetics of continuous-release carbidopa/levodopa. , 1994, Clinical neuropharmacology.

[1223]  D. Tannenbaum,et al.  Plasma Concentrations of Dothiepin and Its Metabolites Are Not Correlated with Clinical Efficacy in Major Depressive Illness , 1993, Therapeutic drug monitoring.

[1224]  S. Preskorn,et al.  Therapeutic drug monitoring. Principles and practice. , 1993, The Psychiatric clinics of North America.

[1225]  S. Nelson,et al.  Inhibition and induction of cytochrome P4502E1‐catalyzed oxidation by isoniazid in humans , 1993, Clinical pharmacology and therapeutics.

[1226]  Y. Masubuchi,et al.  Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes. , 1993, Biochemical and biophysical research communications.

[1227]  M. Seiberling,et al.  [Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure]. , 1993, Medizinische Klinik.

[1228]  R. Rahmani,et al.  Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism , 1993, Fundamental & clinical pharmacology.

[1229]  H. Möller,et al.  Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects , 1993, European Neuropsychopharmacology.

[1230]  S. Arndt,et al.  Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. , 1993, Journal of clinical psychopharmacology.

[1231]  T. Cooper,et al.  Human brain fluoxetine concentrations. , 1993, The Journal of neuropsychiatry and clinical neurosciences.

[1232]  S. Garattini,et al.  Pharmacokinetic and pharmacodynamic significance of antidepressant drug metabolites. , 1992, Pharmacological research.

[1233]  J. Krska,et al.  Serum drug level monitoring in affective disorders , 1992, Journal of clinical pharmacy and therapeutics.

[1234]  B. Johansson A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites , 1992, Acta psychiatrica Scandinavica. Supplementum.

[1235]  H. Wetzel,et al.  Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. , 1992, Clinical chemistry.

[1236]  C M Metzler,et al.  Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time , 1992, Clinical pharmacology and therapeutics.

[1237]  Karen J. Klamerus,et al.  Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite , 1992, Journal of clinical pharmacology.

[1238]  C. Hiemke,et al.  Column switching and high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum. , 1992, Journal of chromatography.

[1239]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[1240]  U. Fuhr,et al.  Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro , 1992, Antimicrobial Agents and Chemotherapy.

[1241]  S. Preskorn,et al.  Tricyclic antidepressant-induced seizures and plasma drug concentration. , 1992, The Journal of clinical psychiatry.

[1242]  K. Yonkers,et al.  Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. , 1992, The American journal of psychiatry.

[1243]  E. Krenzelok,et al.  Acute fluoxetine overdose: a report of 234 cases. , 1992, The American journal of emergency medicine.

[1244]  K. Brøsen,et al.  Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.

[1245]  P. Baumann,et al.  Dextromethorphan and Mephenytoin Phenotyping of Patients Treated with Thioridazine or Amitriptyline , 1992, Therapeutic drug monitoring.

[1246]  G. Granneman,et al.  Effects of 2 Quinolone Antibacterials, Temafloxacin and Enoxacin, on Theophylline Pharmacokinetics , 1992, Clinical pharmacokinetics.

[1247]  F. Bressolle,et al.  Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans. , 1992, Journal of pharmaceutical sciences.

[1248]  F. Vuille,et al.  Use of Plasma Level Monitoring of Antidepressants in Clinical Practice , 1991, Pharmacopsychiatry.

[1249]  J. M. Holbrook,et al.  Clinical monitoring guidelines for neuroleptic and antidepressant drugs. Central State Hospital, Milledgeville, Georgia. , 1991, Hospital pharmacy.

[1250]  R. Cadoret,et al.  Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. , 1991, The American journal of psychiatry.

[1251]  D. Munjack,et al.  Alprazolam levels and response in panic disorder: preliminary results. , 1991, Journal of clinical psychopharmacology.

[1252]  S. Preskorn,et al.  Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. , 1991, The Journal of clinical psychiatry.

[1253]  S. Marder,et al.  Neuroleptic plasma levels. , 1991, Schizophrenia bulletin.

[1254]  D. H. Schroeder,et al.  Therapeutic drug monitoring of bupropion. , 1990, The American journal of psychiatry.

[1255]  A. Iliadis,et al.  Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers , 1990, Fundamental & clinical pharmacology.

[1256]  E. Perucca,et al.  The disposition of primidone in elderly patients. , 1990, British journal of clinical pharmacology.

[1257]  P. Gele,et al.  The metabolic pathways of tianeptine, a new antidepressant, in healthy volunteers. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[1258]  A. Guberman,et al.  Add-on Trial of Clobazam in Intractable Adult Epilepsy with Plasma Level Correlations , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[1259]  F. Simons,et al.  Diphenhydramine: Pharmacokinetics and Pharmacodynamics in Elderly Adults, Young Adults, and Children , 1990, Journal of clinical pharmacology.

[1260]  M. Thase,et al.  Plasma Tranylcypromine: Relationship to Pharmacokinetic Variables and Clinical Antidepressant Actions , 1990, Journal of clinical psychopharmacology.

[1261]  R. Day,et al.  Compliance with Criteria Necessary for Effective Drug Concentration Monitoring , 1990, Therapeutic drug monitoring.

[1262]  F. Sallee,et al.  Clinical Pharmacokinetics of Imipramine and Desipramine , 1990, Clinical pharmacokinetics.

[1263]  J. Rabey,et al.  Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinson's disease , 1990, Acta Neurologica Scandinavica.

[1264]  S. Preskorn,et al.  Central Nervous System Toxicity of Tricyclic Antidepressants: Phenomenology, Course, Risk Factors, and Role of Therapeutic Drug Monitoring , 1990, Journal of clinical psychopharmacology.

[1265]  G. Jones,et al.  Post-mortem drug redistribution--a toxicological nightmare. , 1990, Forensic science international.

[1266]  S. Kitazawa [Therapeutic drug monitoring of ethosuximide]. , 1990, Nihon rinsho. Japanese journal of clinical medicine.

[1267]  D. Wyse,et al.  Melperone: Electrophysiologic and Antiarrhythmic Activity in Humans , 1990, Journal of cardiovascular pharmacology.

[1268]  R. Seifert Therapeutic Drug Monitoring: Psychotropic Drugs , 1989 .

[1269]  M. Jann,et al.  Pharmacokinetics of Haloperidol , 1989, Clinical pharmacokinetics.

[1270]  L. Balant,et al.  Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo. , 1989, Pharmacopsychiatry.

[1271]  D. Greenblatt,et al.  A Large‐Sample Study of Diazepam Pharmacokinetics , 1989, Therapeutic drug monitoring.

[1272]  K. Midha,et al.  Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study. , 1989, Journal of pharmaceutical sciences.

[1273]  Orsulak Pj Therapeutic monitoring of antidepressant drugs: guidelines updated , 1989 .

[1274]  F. Simons,et al.  The Pharmacokinetics and Pharmacodynamics of Hydroxyzine in Patients with Primary Biliary Cirrhosis , 1989, Journal of clinical pharmacology.

[1275]  C. Bye,et al.  Paroxetine plasma levels: lack of correlation with efficacy or adverse events , 1989, Acta psychiatrica Scandinavica. Supplementum.

[1276]  D. Greenblatt,et al.  Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo , 1989, Clinical pharmacology and therapeutics.

[1277]  P. Orsulak Therapeutic monitoring of antidepressant drugs: guidelines updated. , 1989, Therapeutic drug monitoring.

[1278]  R. Defrance,et al.  Influence of Food on Tianeptine and Its Main Metabolite Kinetics , 1988, Journal of clinical pharmacology.

[1279]  J. Filser,et al.  Pharmacokinetics of amitriptyline and amitriptylinoxide after intravenous or oral administration in humans. , 1988, Pharmacopsychiatry.

[1280]  S. Urien,et al.  Effects of the Binding of Imipramine to Erythrocytes and Plasma Proteins on Its Transport Through the Rat Blood‐Brain Barrier , 1988, Journal of neurochemistry.

[1281]  J. P. Gonzalez,et al.  Naltrexone , 1988, Drugs.

[1282]  W J Jusko,et al.  Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. , 1988, Journal of clinical psychopharmacology.

[1283]  F. Aoki,et al.  Clinical Pharmacokinetics of Amantadine Hydrochloride , 1988, Clinical pharmacokinetics.

[1284]  M. Ansseau,et al.  Comparison of sublingual and oral prazepam in normal subjects. II. Pharmacokinetic and pharmacodynamic data. , 1988, Neuropsychobiology.

[1285]  C. Montigny,et al.  A Comparative Double‐Blind Controlled Study of Trimipramine and Amitriptyline in Major Depression: Lack of Correlation with 5‐Hydroxytryptamine Reuptake Blockade , 1987, Journal of clinical psychopharmacology.

[1286]  B. Pfohl,et al.  The Relationship Between Antidepressant Response and Tricyclic Antidepressant Plasma Concentrations , 1987, Clinical pharmacokinetics.

[1287]  F. Sallee,et al.  Pharmacokinetics of Pimozide in Adults and Children with Tourette's Syndrome , 1987, Journal of clinical pharmacology.

[1288]  M. Wachi,et al.  Clinical effects and plasma concentrations of long‐term clonazepam monotherapy in previously untreated epileptics , 1987, Acta neurologica Scandinavica.

[1289]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[1290]  D. Greenblatt,et al.  Bromazepam pharmacokinetics: Influence of age, gender, oral contraceptives, cimetidine, and propranolol , 1987, Clinical pharmacology and therapeutics.

[1291]  D. Weidler,et al.  Nalmefene: Safety and Kinetics After Single and Multiple Oral Doses of a New Opioid Antagonist , 1987, Journal of clinical pharmacology.

[1292]  The Scottish First Episode Schizophrenia Study: II. Treatment: Pimozide Versus Flupenthixol , 1987, British Journal of Psychiatry.

[1293]  S. Pendlebury,et al.  Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. , 1987, Clinical and experimental neurology.

[1294]  P. Hrdina,et al.  Plasma Levels of Maprotiline and Zimelidine and Their Relationship to Clinical Response in Depressed Patients , 1986, Therapeutic drug monitoring.

[1295]  Bromazepam and lorazepam in generalized anxiety: a placebo‐controlled study with measurement of drug plasma concentrations , 1986, Acta psychiatrica Scandinavica.

[1296]  Orsulak Pj Therapeutic monitoring of antidepressant drugs: current methodology and applications. , 1986 .

[1297]  T. Tomson,et al.  Pharmacokinetics: Time‐Dependent Changes— Autoinduction of Carbamazepine Epoxidation , 1986, Journal of clinical pharmacology.

[1298]  D. Giesing,et al.  Pharmacokinetics of dothiepin in humans: a single dose dose-proportionality study. , 1986, Journal of pharmaceutical sciences.

[1299]  Preskorn Sh Tricyclic antidepressant plasma level monitoring: an improvement over the dose-response approach. , 1986 .

[1300]  P. Orsulak Therapeutic monitoring of antidepressant drugs: current methodology and applications. , 1986, The Journal of clinical psychiatry.

[1301]  S. Preskorn Tricyclic antidepressant plasma level monitoring: an improvement over the dose-response approach. , 1986, Journal of Clinical Psychiatry.

[1302]  L. Balant,et al.  Plasma flupentixol concentrations and clinical response in acute schizophrenia. , 1985, Therapeutic drug monitoring.

[1303]  Brian Whiting,et al.  THERAPEUTIC DRUG MONITORING , 1982, The Lancet.

[1304]  B. Pfohl,et al.  Relationship of free nortriptyline levels to therapeutic response , 1985, Acta psychiatrica Scandinavica.

[1305]  M. Jann,et al.  Effects of smoking on fluphenazine clearance in psychiatric inpatients , 1985, Biological Psychiatry.

[1306]  D. Greenblatt,et al.  Imipramine and desipramine disposition in the elderly. , 1985, The Journal of pharmacology and experimental therapeutics.

[1307]  S. A. Simmons,et al.  Cost-benefit analysis of prospective pharmacokinetic dosing of nortriptyline in depressed inpatients. , 1985, Journal of affective disorders.

[1308]  B. Mellström,et al.  Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes , 1984, Clinical pharmacology and therapeutics.

[1309]  M. D. Faiman,et al.  Elimination kinetics of disulfiram in alcoholics after single and repeated doses , 1984, Clinical pharmacology and therapeutics.

[1310]  A. Nicholson,et al.  Pharmacodynamic correlates of modified absorption: studies with lormetazepam. , 1984, British journal of clinical pharmacology.

[1311]  I. Oswald,et al.  Effects of lormetazepam and of flurazepam on sleep. , 1984, British journal of clinical pharmacology.

[1312]  C. Hallett,et al.  Bromazepam: acute benefit-risk assessment in general practice. , 1984, Current medical research and opinion.

[1313]  M. Tsuang,et al.  Pharmacokinetic protocol for predicting plasma nortriptyline levels. , 1983, Journal of clinical psychopharmacology.

[1314]  W. Rein,et al.  Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data. , 1983, Pharmacopsychiatria.

[1315]  A. Moffat,et al.  A Collection of Therapeutic, Toxic and Fatal Blood Drug Concentrations in Man , 1983, Human toxicology.

[1316]  D. Greenblatt,et al.  Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. , 1983, Journal of clinical psychopharmacology.

[1317]  D. Breimer,et al.  Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. , 1983, British journal of clinical pharmacology.

[1318]  D. Greenblatt,et al.  Pharmacokinetic properties of benzodiazepine hypnotics. , 1983, Journal of clinical psychopharmacology.

[1319]  J. Houston,et al.  Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. , 1983, British journal of clinical pharmacology.

[1320]  D. Mungall Applied Clinical Pharmacokinetics , 1983 .

[1321]  H. Gaertner,et al.  Response to maprotiline treatment in depressive patients relationship to urinary MHPG excretion and plasma drug level. , 1982, Pharmacopsychiatria.

[1322]  E. Änggård,et al.  Clinical Pharmacokinetics of Methadone , 1982, Acta anaesthesiologica Scandinavica. Supplementum.

[1323]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[1324]  S. Dahl Active Metabolites of Neuroleptic Drugs: Possible Contribution to Therapeutic and Toxic Effects , 1982, Therapeutic drug monitoring.

[1325]  J. Daugirdas,et al.  Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. , 1982, Clinical nephrology.

[1326]  P. Baumann,et al.  On the relationship between free plasma and saliva amitriptyline and nortriptyline. , 1982, International pharmacopsychiatry.

[1327]  D. Greenblatt,et al.  Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs , 1981, Clinical pharmacology and therapeutics.

[1328]  Trevor R. Norman,et al.  Metabolism and pharmacokinetics of dothiepin. , 1981, British journal of clinical pharmacology.

[1329]  D. Brater,et al.  Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. , 1981, Annals of internal medicine.

[1330]  J. Rees Clinical Interpretation of Pharmacokinetic Data on Dothiepin Hydrochloride (Dosulepin, Prothiaden) , 1981, The Journal of international medical research.

[1331]  H. Kuss,et al.  Quantitative high-performance liquid chromatographic assay for the determination of maprotiline and oxaprotiline in human plasma. , 1981, Journal of chromatography.

[1332]  A. Coppen,et al.  Clinical State, Plasma Levels of Haloperidol and Prolactin: A Correlation Study in Chronic Schizophrenia , 1980, British Journal of Psychiatry.

[1333]  J S Harmatz,et al.  Oxazepam kinetics: effects of age and sex. , 1980, The Journal of pharmacology and experimental therapeutics.

[1334]  D. Greenblatt,et al.  Desmethyldiazepam kinetics in the elderly after oral prazepam , 1980, Clinical pharmacology and therapeutics.

[1335]  J. Kiechel Pharmacokinetics and metabolism of guanfacine in man: a review. , 1980, British journal of clinical pharmacology.

[1336]  R. Dixon,et al.  Chlordiazepoxide concentrations in saliva and plasma measured by radioimmunoassay. , 1980, Research communications in chemical pathology and pharmacology.

[1337]  D. R. Hawkins,et al.  The metabolic fate of Sormodren (bornaprine hydrochloride) in animals and humans. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[1338]  Trevor R. Norman,et al.  Pharmacokinetics of nortriptyline in elderly volunteers. , 1980, Communications in psychopharmacology.

[1339]  J. Dubois,et al.  The bioavailability of oral and parenteral chlorimipramine (Anafranil). , 1980, Progress in neuro-psychopharmacology.

[1340]  C. Speicher,et al.  The Importance of Request and Report Forms in the Interpretation of Therapeutic Drug Monitoring Data , 1980, Therapeutic drug monitoring.

[1341]  D. Greenblatt,et al.  Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. , 1980, Journal of pharmaceutical sciences.

[1342]  D. M. Hailey,et al.  Plasma concentrations of medazepam and its metabolites after oral administration. , 1979, British journal of anaesthesia.

[1343]  [Metabolism of antiparkinson drugs. An example of competitive hydroxylation]. , 1979, Arzneimittel-Forschung.

[1344]  J. Schildkraut,et al.  Guidelines for therapeutic monitoring of tricyclic antidepressant plasma levels. , 1979, Therapeutic drug monitoring.

[1345]  R. McAuley,et al.  Relationship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single night-time and divided daily dose regimens. , 1978, British journal of clinical pharmacology.

[1346]  A. Coppen,et al.  Workshop on the clinical pharmacology and efficacy of mianserin. , 1978, British journal of clinical pharmacology.

[1347]  T. Cooper Plasma Level Monitoring of Antipsychotic Drugs , 1978, Clinical pharmacokinetics.

[1348]  A. Baruzzi,et al.  Carbamazepine and carbamazepine-10, 11-epoxide concentrations in human brain. , 1977, British journal of clinical pharmacology.

[1349]  G. Tognoni,et al.  Plasma levels of di-no-propylacetate and clonazepam in epileptic patients. , 1977, International journal of clinical pharmacology and biopharmacy.

[1350]  A Amdisen,et al.  Serum Level Monitoring and Clinical Pharmacokinetics of Lithium , 1977, Clinical pharmacokinetics.

[1351]  J. Fleiss,et al.  Clinical implications of imipramine plasma levels for depressive illness. , 1977, Archives of general psychiatry.

[1352]  S. D. Soni Fluspirilene in the treatment of non-hospitalized schizophrenic patients. , 1977, Current medical research and opinion.

[1353]  P. Kragh‐Sørensen,et al.  Clinical pharmacokinetic studies of perphenazine. , 1976, British journal of clinical pharmacology.

[1354]  B. Dvorchik,et al.  Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. , 1976, Clinical chemistry.

[1355]  H. Hucker,et al.  Further studies on the metabolism of carbidopa, (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate, in the human, Rhesus monkey, dog, and rat. , 1975, Journal of medicinal chemistry.

[1356]  C. Puglisi,et al.  Blood level profile in man following chronic oral administration of flurazepam hydrochloride. , 1973, Journal of pharmaceutical sciences.

[1357]  L. Lasagna,et al.  Effects of mode of management on plasma chlorpromazine in psychiatric patients , 1973, Clinical pharmacology and therapeutics.

[1358]  M. Åsberg,et al.  Relationship between Plasma Level and Therapeutic Effect of Nortriptyline , 1971, British medical journal.

[1359]  M. A. Schwartz,et al.  Metabolism of flurazepam, a benzodiazepine, in man and dog. , 1970, Journal of pharmaceutical sciences.

[1360]  M. Åsberg,et al.  Correlation of Subjective Side Effects with Plasma Concentrations of Nortriptyline , 1970, British medical journal.

[1361]  A Controlled Trial of Prothipendyl (Tolnate) in Mentally Subnormal Patients , 1966, British Journal of Psychiatry.

[1362]  F. H. Dost,et al.  Der Blutspiegel : Kinetik der Konzentrationsabläufe in der Kreislaufflüssigkeit , 1953 .